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Staphylococcus	 aureus	 is	 an	 opportunistic	 pathogenic	 bacterium	 known	






aureus	wild	 type	 and	 lgt	 strains	 showed	 that,	S.	aureus	 lipoproteins	 contribute	
towards	 binding	 of	 the	 pathogen	 to	 platelets.	 	 Lipoproteins	 present	 in	
extracellular	milieu	also	bind	platelets.	Platelet	spreading,	 thrombus	formation,	
agonist	 induced	 platelet	 aggregation	 and	 αIIbβ3	 activation	 were	 inhibited	 by	
cell-free	lipoproteins.		
CD36	 was	 identified	 as	 the	 major	 platelet	 surface	 molecule	 interacting	
with	 S.	 aureus	 lipoproteins.	 	 Antibody	 neutralization	 demonstrated	 that	
functional	inhibition	of	platelet	activation	caused	by	lipoproteins	was	via	CD36.	
Pre-incubation	of	platelets	with	S.	aureus	lipoproteins	significantly	increased	the	
association	of	CD36	with	 integrin	β3.	Thus	CD36-β3	association	 is	proposed	 to	













































































































































































































































































































































et	 al.	 1976).	 Most	 of	 the	 bacteria	 in	 this	 genus	 are	 part	 of	 the	 normal	 human	
microbiota	 and	 are	 inhabitants	 of	 the	 upper	 respiratory	 tract	 (Pettigrew	 et	al.	
2008),	 skin	 (Chiller	 et	 al.	 2001),	 gut	 (Sannasiddappa	 et	 al.	 2011)	 and	 vagina	
(Weinstein	1938).	Some	are	opportunistic	pathogens	and	belong	to	the	group	of	
invasive	 Gram-positive	 pyogenic	 cocci	 (Finlay	&	 Falkow	1997).	 Based	 on	 their	
ability	to	produce	coagulase	that	can	convert	 fibrinogen	to	fibrin	(Tager	1974),	
Staphylococci	 are	 classified	 as	 coagulase	 positive	 or	 negative	 (Baird-Parker	
1963).	Some	Staphylococci	produce	capsule	and	slime	which	gives	this	bacterium	
the	 ability	 to	 evade	 immune	 response	by	 inhibiting	neutrophil	 chemotaxis	 and	
phagocytosis	 (Barrio	 et	 al.	 2000;	 Johnson	 et	 al.	 1986).	 Slime	 also	 helps	 in	
providing	resistance	against	antimicrobial	agents	(Souli	et	al.	1998).		
1.1.	Staphylococcus	aureus	
Staphylococcus	 aureus	 is	 a	 major	 pathogenic	 bacterium	 of	 humans	 and	
animals.	 Most	 of	 S.	 aureus	 (“aureus”	 is	 latin	 for	 golden)	 strains	 give	 golden	
colonies	 on	 the	 rich	 medium	 due	 to	 production	 of	 yellow	 pigment,	
staphyloxanthin	(Pelz	et	al.	2005).	Staphyloxanthin	gives	S.	aureus	the	ability	to	





S.	 aureus	 expresses	 different	 surface	 proteins	 like	 fibronectin	 binding	
proteins	(FnBP)	(Roche	et	al.	2004),	clumping	 factors	A	and	B	(L.	O’Brien	et	al.	
2002),	 Serine-Aspartate	 Repeat	 Proteins	 (Sdr)	 (Sabat	 et	 al.	 2006),	 S.	 aureus	
Protein	A	(SpA)	(Kobayashi	&	DeLeo	2013),	Iron	regulated	surface	determinant	
protein	A	(IsdA)	(Clarke	et	al.	2009),	 	which	aid	in	its	adhesion	to	host	surfaces	
(Figure	 1.1).	 FnBPs	 are	 one	 of	 the	 important	 microbial	 surface	 components	
recognizing	 adhesive	matrix	molecules	 (MSCRAMMs)	 (O’Neill	 et	 al.	 2008)	 and	
can	bind	to	fibronectin	(O’Neill	et	al.	2008),	 fibrinogen	and	elastin	(Keane	et	al.	
2007).	 FnBPs	 also	 interact	 with	 integrin	 α5β1	 on	 host	 cells	 via	 a	 fibronectin	
bridge,	which	allows	S.	aureus	 to	bind	and	invade	endothelial	cells	(Schröder	et	
al.	 2006),	 epithelial	 cells	 (Medina-Estrada	 et	 al.	 2015),	 fibroblasts	 and	
keratinocytes	 (Kintarak	 et	 al.	 2004).	 S.	 aureus	 strains	 deficient	 in	 FnBPs	 lack	
invasiveness	 and	 ability	 to	 cause	 sepsis	 (Edwards	 et	 al.	 2010).	 FnBPs	 are	
associated	with	biofilm	formation	capabilities	of	S.	aureus	MRSA	strains	(O’Neill	
et	al.	2008).	
S.	aureus	 expresses	 clumping	 factors	 (Clf)	which	 can	 bind	 to	 fibrinogen	
(Ní	Eidhin	et	al.	 1998).	Two	clumping	 factors	are	produced	by	S.	aureus	 –	ClfA	
and	B	 (Foster	et	al.	 1998),	which	have	different	binding	abilities.	ClfA	binds	 to	
the	extreme	C	terminus	of	the	γ-chain	(McDevitt	et	al.	1997),	whereas	ClfB	binds	
to	the	α-chain	of	fibrinogen	(Ní	Eidhin	et	al.	1998).	ClfA	binding	to	fibrinogen	in	





2002)	 and	 squamous	 epithelial	 cell	 envelope	 protein	 loricrin	 (Mulcahy	 et	 al.	
2012).	ClfB	binds	to	dermokine,	thus	showing	binding	ability	to	multiple	ligands	
(Xiang	et	al.	2012).		
Another	 important	 set	 of	 MCRAMMs	 are	 the	 Serine-Aspartate	 Repeat	
Proteins	(Sdr)	(Foster	et	al.	1998).	Three	Sdr	proteins	are	expressed	by	S.	aureus	
-	 Sdr	 C,	 D	 and	 E	 (Sabat	 et	 al.	 2006).	 SdrC	 binds	 to	 cultured	 mammalian	 cells	
expressing	 β-neurexin	 (Barbu	 et	 al.	 2010).	 SdrC	 is	 also	 involved	 in	 biofilm	




are	 present	 in	 the	 cornified	 envelope	 of	 human	 desquamated	 epithelial	 cells.	
Along	with	binding	to	cellular	and	extracellular	matrix	components,	 IsdA	binds	




nasal	 epithelial	 cells	 (Aly	 et	 al.	 1980).	 Wall	 teichoic	 acid	 on	 the	 surface	 of	 S.	
aureus	 is	 significant	 in	 binding	 to	 epithelial	 cells	 (Baur	 et	 al.	 2014)	 and	 wall	
teichoic	acid	deficient	S.	aureus	strains	show	an	inability	to	cause	endocarditis	in	
rabbits	 (Weidenmaier	 et	 al.	 2005).	 The	 charge	 distribution	 caused	 by	 teichoic	
acid	is	speculated	to	be	important	in	binding	of	S.	aureus	to	artificial	surface	(e.g.	
surgical	 or	medical	 devices)	 (Gross	 et	 al.	 2001).	 	Wall	 teichoic	 acids	 on	 the	 S.	
aureus	 surface	 also	 confer	 immune	 resistance	 by	 blocking	 binding	 of	
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antimicrobial	 fatty	 acids	 (Kohler	 et	 al.	 2009)	 and	 antibodies	 to	 the	 surface	
epitopes	on	S.	aureus	(Gautam	et	al.	2015).		
1.1.2.	S.	aureus	invasion	strategies		
	 S.	aureus	 breaches	host	protective	barriers	by	 secreting	different	 toxins.	
These	 include	 toxic	 shock	 syndrome	 toxin	 1	 (TSST-1),	 exfoliative	 toxins	 (ETs)	
and	haemolysins	(Johnson	et	al.	1991).	Toxic	shock	syndrome	toxin	1	(TSST-1)	is	
the	major	cause	of	Toxic	shock	syndrome,	which	is	characterized	by	fever,	rash,	
hypotension,	multiple-organ-system	dysfunction	 and	 desquamation	 (Parsonnet	
et	 al.	 2008).	 TSST-1	 is	 a	 pyrogenic	 superantigen	 (Wahlsten	 et	 al.	 1998).	 It	
stimulates	 T-	 cell	 and	 monocyte	 mediated	 massive	 cytokine	 (TNF	 and	 IL-1)	
release	resulting	in	hyper	immune	response	and	cellular	damage	(Miethke	et	al.	
1993).	 Exfoliative	 toxins	 are	 the	 major	 factor	 in	 pathogenesis	 of	 scalded	 skin	
syndrome	and	one	of	the	significant	factors	in	aiding	entry	of	bacteria	into	blood	
(Bukowski	et	al.	 2010).	 These	 toxins	 are	proteases	 and	 act	 on	desmoglein-1,	 a	




(Wiseman	 1975).	 S.	 aureus	 strains	 deficient	 in	 α-toxin	 are	 attenuated	 for	
invasiveness	(Patel	et	al.	1987).		These	toxins	can	form	small	pores	which	result	
in	cellular	damage	due	to	osmotic	imbalance	(Krasilnikov	et	al.	1988).	Along	with	
that,	 the	 pores	 caused	 by	 these	 toxins	 also	 result	 in	 secondary	 effects	 like	






(Kobayashi	&	DeLeo	 2013)	 and	 extracellular	 fibrinogen	 binding	 proteins	 (Efb)	
(Georgoutsou-Spyridonos	et	al.	2015)	modulate	immune	function.	SpA,	released	







A.	 S.	 aureus	 surface	proteins	 adhering	with	host	 cell	 proteins	 playing	 significant	





Neutrophil	 phagocytosis	 is	 the	 most	 efficient	 way	 to	 clear	 an	 S.	 aureus	
infection	 (Rigby	 &	 DeLeo	 2012).	 The	 pathogen	 has	 developed	 many	 anti	 –	









to	 form	 plasmin	which	 then	 acts	 as	 a	 bacterial	 surface-bound	 serein	 protease,	
which	 can	 cleave	 IgG	 and	 C3b	 at	 the	 bacterial	 surface,	 thus	 inhibiting	
phagocytosis	(Rooijakkers	et	al.	2005).		S.	aureus	has	also	developed	strategies	to	
survive	 in	 phagocytic	 cell	 (Gresham	 et	 al.	 2000).	 It	 can	 neutralize	 Reactive	
Oxygen	 Species	 (ROI’s)	 by	 producing	 catalase	 and	 superoxide	 dismutase	
(Mandell	 1975)	 and	 can	 produce	 toxins,	 like	 phenol-soluble	 modulins	 and	
leukocidin	AB,	 that	 lyse	 the	neutrophil	after	phagocytosis	 (DuMont	et	al.	2013;	
Surewaard	et	al.	2013).	This	ability	of	S.	aureus	helps	it	to	survive	and	spread	in	
different	sites	of	the	body	using	immune	cells	as	a	vehicle	(Gresham	et	al.	2000).	
One	 of	 the	 efficient	 microbicidal	 activities	 of	 neutrophils	 is	 production	 of	
Neutrophil	 Extracellular	Traps	 (NETs).	The	NETs	 are	made	of	 neutrophil	DNA,	
and	granular	anti-microbial	proteins,	 in	which	microbes	are	 trapped	and	killed	
(Zawrotniak	 et	al.	 2013).	 S.	 aureus	 produces	 nuclease	 and	 adenosine	 synthase	
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which	 convert	 NET’s	 to	 deoxyadenosine	 and	 neutralize	 their	 effect	
(Thammavongsa	et	al.	2013).		
The	 ability	 of	 S.	 aureus	 to	 produce	 a	 biofilm	 also	 aids	 its	 survival	 and	
dissemination	(Archer	et	al.	2011).	Biofilm	has	an	altered	phenotype	with	regard	
to	 growth,	 gene	 expression	 and	 protein	 production	 (Donlan	 et	 al.	 2002).	 On	
exposure	 to	 biofilm	 promoting	 conditions,	 like	 an	 anaerobic	 environment,	
osmotic	 imbalance,	 change	 in	 temperature	and	exposure	 to	glucose,	 ethanol	or	
antibiotics,	S.	aureus	enhances	expression	of	genes	that	promotes	production	of	
molecules	 essential	 for	 biofilm	 formation	 (Archer	 et	 al.	 2011).	 For	 example,	
production	of	polysaccharide	intercellular	antigen	(PIA),	a	major	component	in	S.	
aureus	 biofilm,	 is	 enhanced	 in	 anaerobic	 conditions	 (Cramton	 et	 al.	 2001).	 S.	
aureus	 biofilms	 are	 associated	with	 diseases	 like	 osteomyelitis,	 chronic	wound	
infections,	 chronic	 rhinosinusitis,	 endocarditis,	 ocular	 infections	 and	 poly	
microbial	 biofilm	 infections	 (Figure	 1.3)	 (Archer	 et	 al.	 2011).	 The	 efficient	
biofilm	formation	ability	also	aids	in	survival	of	S.	aureus	on	medical	devices	like	








Figure	 1.2:	 S.	 aureus	 evasion	 strategies.	 S.	 aureus	 produce	 proteins	 that	 can	
bind	the	Fc	portion	of	antibody	and	complement	components	thus	inhibit	antibody	
and	 complement	mediated	 phagocytosis.	 Toxins	 produced	 by	S.	 aureus	 can	 form	












S.	 aureus	 is	 an	 opportunistic	 pathogen	 that	 uses	 multiple	 strategies	 to	
adhere,	invade	and	survive	in	the	host	and	it	has	the	ability	to	cause	infection	at	
numerous	sites	in	the	human	body	(Figure	1.3).	S.	aureus	is	a	part	of	the	normal	
human	 skin	 flora,	 but	 opportunistically	 causes	 mild	 skin	 infections	 such	 as	
pimples,	 boils,	 impetigo,	 folliculitis,	 to	 severe	 skin	 infection	 like	 furuncle	 and	
necrotizing	 fasciitis	 (Lina	 et	 al.	 1999).	 S.	 aureus	 skin	 infections,	 even	 though	
begin	 as	 minor	 boils	 or	 abscesses,	 if	 left	 untreated	 can	 progress	 to	 severe	
systemic	diseases	(McCaig	et	al.	2006).		
The	 ability	 of	 S.	 aureus	 to	 produce	 enterotoxins	 makes	 it	 one	 of	 the	
leading	 cause	 of	 food	 poisoning	 (Bhatia	 et	 al.	 2007),	 which	manifests	 itself	 as	








(Wardenburg	 et	 al.	 2007).	 S.	 aureus	 can	 also	 gain	 entry	 into	 the	 bloodstream	
through	 intravenous	 infusion,	 transducer	 respiratory	 devices,	 prostheses,	
catheters,	 endoscopes	 or	 via	 hemodialysis,	 all	 of	which	 can	 lead	 to	 bacteremia	
(Locksley	1982).	S.	aureus	bacteremia	allows	the	pathogen	to	spread	to	different	
organs.	 Entry	 of	 the	 bacterium	 into	 lymph	 node	 leads	 to	 widespread	 seeding	
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numerous	 adhesive	 strategies	 S.	 aureus	 can	 bind	 to	 intact	 or	 damaged	 heart	
valve	surface	(Werden	et	al.	2014).	Damage	to	endothelium	activates	the	normal	
hemostasis	system	that	works	on	to	repair	the	damage	by	forming	a	thrombus.	
The	 thrombus	 consists	 of	 plasma	 proteins	 (like	 fibrinogen)	 and	 cells,	 most	
predominantly	 platelets	 (Werden	 et	 al.	 2014).	 The	 platelets	 present	 on	 the	
developing	 thrombus	are	proposed	 to	provide	binding	 foci	 to	 the	 circulating	S.	
aureus,	 thus	in	turn	provide	seeding	ground	for	bacteria	(Sullam	et	al.	1996).	S.	
aureus	 are	 found	 to	 be	 present	 in	 the	 occluded	 thrombi	 associated	 with	 the	
infective	endocarditis	(Pawar	et	al.	2004).		
Bacterial	 endocarditis	 is	 characterized	 by	 inflamed	 endothelium	 and	
associated	lesions	on	the	heart	valve	(Werden	et	al.	2014).	Ability	of	S.	aureus	to	
adhere	 and	 invade	 host	 endothelium	 is	 proposed	 to	 play	 significant	 part	 in	
inflammatory	 lesion	 associated	 endocarditis.	 Super	 antigenicity	 property	 of	 S.	
aureus	 surface	 and	 secreted	 proteins	 leads	 to	 inflammatory	 response	 causing	
damage	 to	 the	 intact	 host	 endothelium	 and	 formation	 of	 lesions	 (Becker	 et	al.	
2014).	 These	 inflammatory	 lesions	 on	 heart	 valve	 provide	 niche	 for	 the	
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settlement	 of	 S.	 aureus,	 where	 they	 interact	 with	 circulating	 platelets	 causing	
their	 activation	 and	 aggregation,	 forming	 an	 infected	 thrombus	 on	 the	 valve	
surface	 (L.	 O’Brien	 et	al.	 2002).	Modulation	 of	 platelet	 function	 by	S.	aureus	 is	
speculated	 to	 play	 significant	 role	 in	 pathogenesis	 of	 infective	 endocarditis	
(Ganesh	et	al.	2008).	Adhesion	and	activation	of	platelets	surrounding	S.	aureus	






Figure	 1.3:	 Sites	 for	 colonisation	 of	 S.	 aureus	 on	 humans	 and	 associated	
infections.	1.	Tissues	where	S.	aureus	is	often	found	but	does	not	cause	disease,	2.	
Pimples	 and	 impetigo,	 3.	 Boils	 and	 carbuncles	 on	 any	 surface	 area,	 4.	 Wound	
infection	 and	 abscesses,	 5.	 Spread	 to	 lymph	 nodes	 and	 to	 blood	 (septicaemia),	
resulting	in	widespread	seeding,	6.	Osteomyelitis,	7.	Endocarditis,	8.	Meningitis,	9.	




Figure	 1.4:	 Mechanism	 of	 infective	 endocarditis:	 a.	 Valve	 colonization	 as	 a	
consequence	 of	 mechanical	 injury.	 (1)	 Thrombus	 is	 formed	 consisting	 plasma	
proteins	and	platelets.	 (2)	Bacteria	bind	to	clot	via	platelets	and	plasma	proteins	
and	 colonize	 it	 during	 transient	 bacteraemia.	 Adhered	 monocytes	 release	 tissue	
factor	and	cytokines.	 (3)	More	platelets	are	attracted	and	become	activated,	and	




Staphylococcus	 aureus	 adhere	 to	 this	 protein.	 (2)	Bacteria	are	 internalized,	 and	
endothelial	 cells	 release	 tissue	 factor	 and	 cytokines,	 causing	 blood	 clotting	 and	










other	 blood	 cells	 platelets	 are	 also	 produced	 in	 bone	marrow	 from	 very	 large	
precursor	 cells	 called	 megakaryocytes	 (Deutsch	 &	 Tomer	 2006).	 Functionally	
platelets	are	mainly	involved	in	haemostasis	but	have	a	range	of	other	less	well-
understood	 functions,	 such	 as	 inflammation	 (Lindemann	 et	 al.	 2001),	
antimicrobial	host	defence	(Cox	et	al.	2011),	tumor	growth	and	metastasis	(Jurk	





site	 for	platelet	production,	 small	numbers	are	also	produced	 in	blood	and	 the	
lungs	 (Zucker-Franklin	 &	 Philipp	 2000).	 Megakaryocytes	 are	 developed	 from	
pluripotent	 hematopoietic	 progenitors.	 Before	 megakaryocytes	 can	 form	
platelets	 they	become	polyploid	 through	 endomytosis	 (repeated	 cycles	 of	DNA	
replication	without	cell	division)	(Jackson	1990).	Multiple	sets	of	chromosomes	
result	 in	 amplification	 of	 functional	 genes	 thus	 leading	 to	 expression	 of	
functional	 platelet	 proteins	 and	 increase	 the	 cell	 size	 generating	 mature	
megakaryocyte	 (Vitrat	 et	 al.	 1998).	 From	 the	 mature	 megakaryocyte,	 pro-




provide	 tracks	 for	 membranes,	 organelles	 and	 granules	 in	 proplatelets.	 The	
organelles	move	bidirectionally	over	microtubules	until	 trapped	 in	 the	pinched	
off	platelet	(Patel	et	al.	2005).		
The	 life	span	of	circulating	platelets	 is	7	to	10	days	after	which	they	are	
cleared	 in	 the	 liver	 and	 spleen	 (Kaplan	 &	 Saba	 1978).	 Many	 platelet	 surface	
proteins	are	glycosylated	with	a	sialic	acid	cap	(Crook	1991).		Aging	of	platelets	
causes	 removal	 of	 the	 sialic	 acid	 cap	 leading	 to	 exposure	 of	 underlying	 sugar	
galactose.	 Ashwell-Morell	 receptors	 on	 liver	 hepatocytes	 and	 macrophages	
recognize	desialylated	platelets	causing	their	clearance	(Grozovsky	et	al.	2014).		
1.3.2.	Platelet	Activation	




Binding	 of	 platelets:	 Platelet	 adhesion	 is	 determined	 by	 rheological	
conditions	 that	 depend	 on	 the	 velocity	 of	 blood	 in	 the	 vessel	 and	 shear	 rate	
(Varga-Szabo	et	al.	2008).	Shear	rate	occurs	due	to	the	shearing	effects	between	
the	 adjacent	 layers	 of	 fluid	 and	 is	 influenced	 by	 blood	 velocity	 and	 viscosity	





is	 important	 as	 it	 keeps	 platelets	 in	 close	 proximity	 with	 the	 endothelium	
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(Schneider	 et	 al.	 2007).	 GPIb	 binds	 to	 immobilized	 but	 not	 the	 soluble	 vWf.	
Immobilization	 of	 vWf	 leads	 to	 its	 conformational	 change,	 like	 extension	 of	 its	




These	 interactions	 triggers	 intracellular	 signalling	 events	 coupled	 with	
platelet	 G-proteins	 and	 also	 induces	 the	 release	 of	 secondary	 mediator’s;	
adenosine	diphosphate	(ADP)	(Daniel	et	al.	1999)	and	thromboxane	A2	(TXA2)	




adhesion	 resulting	 in	 thrombus	 formation	 (Varga-Szabo	et	al.	 2008;	Nieswandt	
et	al.	2009).	
Spreading	 of	 Platelets:	 Binding	 to	 exposed	 ECM	 surface	molecules	 or	
interaction	with	secreted	agonists	 triggers	changes	 in	platelets,	one	of	which	 is	
characteristic	 shape	 change	 (Lee	 et	 al.	 2012).	 On	 contact,	 a	 platelet	 loses	 its	
discoid	 shape	 and	 becomes	 rounded	 or	 spheroid	 shaped	which	 is	 followed	 by	
formation	of	finger	like	projections	grown	from	the	cell	periphery	(Kuwahara	et	
al.	 2002).	 Later,	 the	 platelet	 flattens	 over	 the	 surface	 and	 broad	 lamellae	 are	








an	 increase	 in	 the	 cytosolic	 calcium	 levels.	 Intracellular	 calcium	 binds	 with	
gelsolin	causing	its	conformational	change.	With	this	new	conformation,	gelsolin	
binds	to	actin,	which	causes	splitting	of	actin	filament	resulting	in	disc	to	sphere	
shape	 change	 (Lind	 et	 al.	 1982).	 Agonist	 stimulus	 to	 platelets	 also	 causes	
activation	 of	 G-proteins	 that	 activate	 Rho	 kinases	 and	 LIM	 kinases	 which	
phosphorylates	 myosin	 light	 chain	 kinases	 and	 cofilin	 (Offermanns	 2006),	




are	 secreted	 on	 activation	 (Flaumenhaft	 2003).	 Platelet	 activation	 causes	 the	
granules	 to	 centralize	 and	 may	 undergo	 homotypic	 fusion	 i.e.	 fuse	 with	 each	
other	prior	to	secretion	(Reed	et	al.	2000).	The	mechanism	of	secretion	involves	
fusion	 of	 granules	 with	 platelet	 open	 canalicular	 system	 (OCS)	 (Flaumenhaft	
2003).	The	OCS	 is	 the	tunneling	 invagination	of	platelet	plasma	membrane	and	
an	 elaborate	 channel	 system	 involved	 in	 pathway	 transport	 of	 substances	 into	
the	cell	and	channels	for	discharge	of	granules	(Escolar	&	White	1991).		
α-	granules	are	the	most	abundant	of	all	platelet	granules	and	are	unique	
to	 platelets	 (Harrison	 &	 Cramer	 1993).	 There	 are	 50	 to	 80	 granules/platelet	
ranging	in	the	size	from	200	to	500	nm	that	occupy	10%	of	platelet	volume.	On	
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activation,	 the	granular	membrane	 fuses	 to	 the	platelet	plasma	membrane	and	
granular	contents	are	released	(Blair	&	Flaumenhaft	2009).	α-	granules	contain	
membrane	 bound	 proteins,	 some	 of	 which	 are	 already	 present	 on	 platelet	
plasma	membrane	like	integrins	(αIIb,	α6,	β3),	immunoglobulin	family	receptors	
(GPVI,	Fc	receptors,	PECAM)	and	other	receptors	like	CD36	and	Glut-3	(Berger	et	
al.	 1996).	 Other	 membrane	 proteins	 specific	 for	 α-granules	 are	 P-selectin,	
fibrocystin-L	 and	 CD109	 that	 are	 only	 expressed	 on	 the	 platelet	 surface	 after	
granule	 release	 (Berman	 et	 al.	 1986).	 There	 are	 known	 to	 be	 more	 than	 300	
soluble	 proteins	 in	 α-	 granules,	 most	 of	 which	 are	 already	 present	 in	 plasma.	
These	soluble	proteins	have	diverse	functions	in	blood	coagulation	(coagulation	
factors,	 pathway	 inhibitors,	 tissue	 factors),	 cell	 adhesion	 (fibrinogen,	 vWf,	
thrombospondin)	 (Stenberg	 et	al.	 1984),	 inflammation,	 cell	 growth	 (epidermal	
growth	 factor,	 hepatocyte	 growth	 factor,	 insulin	 like	 growth	 factor)	 and	 host	
defence	(microbicidal	and	immune	response)	(Blair	&	Flaumenhaft	2009).	
Dense	 granules	 are	 subtypes	 of	 lysosome	 related	 organelles	 and	 are	
fewer	 and	 smaller	 than	 α-	 granules	 (Whiteheart	 2011).	 These	 are	 exclusive	 to	
platelets	 and	 contain	 cations	 (Ca2+,	 Mg2+,	 K+)	 (Ruiz	 et	 al.	 2004),	 phosphates	
(polyphosphates,	 pyrophosphates),	 adenine	 nucleotides	 (ATP,	 ADP,	 GTP,	 UTP)	
(Fogelson	 &	 Wang	 1996)	 and	 bioactive	 amines	 (serotonin,	 histamines)	
(Chatterjee	&	Anderson	1993).	Membranes	of	dense	granules	contains	proteins	
that	are	 typically	present	 in	 lysosome	related	organelle	 like	LAMP-2	and	CD63	
(Israels	et	al.	1996).	
Lysosomes	 in	 platelets	 contain	 enzymes	 that	 are	 present	 in	 other	
nucleated	 cells	 for	 protein	 degradation	 (cathaspin,	 elatase	 etc),	 carbohydrate	
	 34	
degradation	 (glucosidase,	 fucosidase,	 galactosidase	 etc)	 and	 phosphate	 ester	
cleaving	 enzymes	 –	 e.g.	 acid	 phosphatase	 is	 the	 most	 abundant	 (Ciferri	 et	 al.	
2000).	 Lysosome	 contains	 LAMP-1,	 LAMP-2	 and	 CD63	 membrane	 proteins	
(Dell’angelica	2000).	
1.3.5.	Signalling	in	platelet	activation:	
	 Initial	 binding	 of	 platelets	 to	 vWf	 and	 collagen	 via	 GPIb-IX	 and	 GPVI	
respectively,	 induces	 intracellular	 signalling	 in	 platelets	 (Gardiner	 et	al.	 2010).	
GPVI	is	exclusively	present	on	megakaryocytes	and	platelets	(Moroi	et	al.	2004).	
GPVI	consists	of	 two	 immunoglobulins	 like	domains	 in	extracellular	region	and	
exists	as	a	dimer	on	platelets	forming	two	parallel	grooves	providing	binding	site	







cytoplasmic	 domain,	which	 then	 phosphorylate	 ITAM	 (Immune	 tyrosine	 based	
activation	motif)	domain	of	FcRγ	 (Watson	et	al.	 2005).	 Syk	kinase	binds	 to	 the	
phosphorylated	ITAM	domains	and	causes	phosphorylation	of	adaptor	proteins	
(like	LAT,	SLP-76,	Btk’s,	GADS),	which	leads	to	activation	of	PLCγ	(Pasquet	et	al.	
1999).	 Stimulation	 of	 GPIb-IX	 also	 activates	 SFK’s	 and	 PI3	 kinases	 causing	
calcium	release	and	integrin	activation	(Liu	et	al.	2005).	GPIb-IX	is	also	involved	
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platelet	 agonists	 are	 released	 from	 damaged	 cells,	 during	 coagulation,	
inflammation	 and	 from	 activated	 platelets	 which	 contribute	 in	 amplifying	
platelet	 response	 (Li	 et	 al.	 2010).	 These	 molecules	 induce	 platelet	 response	
mainly	via	G-	protein	coupled	receptors	(GPCR’s)	which	belong	to	family	of	seven	
transmembrane	domain	receptors	that	transmit	signal	through	heterotrimeric	G	
-	proteins	which	are	 composed	of	α,	β	and	γ	 subunits	 (Offermanns	2006).	 In	a	
resting	 platelet	 α	 subunit	 exists	 in	 GDP	 bound	 state	 and	 on	 ligand	 binding	 it	
changes	 to	GTP	bound	 state	 and	 is	 released	 form	 the	 trimeric	 complex.	 α-GTP	
bound	complex	in	cytoplasm	interacts	with	downstream	GPCR	signalling	cascade	
and	 causes	platelet	 activation.	β-γ	 complex	 is	 also	 involved	 in	 signalling	which	
involves	PI3Kγ	as	the	downstream	effector	molecule	(Li	et	al.	2010).	Thrombin	
induced	 platelet	 activation	 is	 mediated	 via	 GPCR’s	 called	 protease	 activated	
receptors	 (PAR’s):	 PAR1	 and	 PAR4	 in	 humans	 and	 PAR3	 and	 PAR4	 in	 mice	
(Offermanns	2006).		
Inside-out	signalling		
Platelets	 express	 integrins	 αIIbβ3	(fibrinogen	 receptor),	
α5β3	(vitronectin	 receptor),	 α2β1	(collagen	 receptor),	 α5β1	(fibronectin	
receptor),	and	α6β1	(laminin	receptor)	on	their	surface	(Nieswandt	et	al.	2009).	
Integrin	αIIbβ3	is	the	most	abundant	of	all	and	is	significant	in	platelet	activation	
or	 aggregation.	 It	 is	 present	 in	 an	 inactive	 form	 (low	 affinity	 form)	 and	 on	
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stimulation	 of	 platelets,	 intracellular	 signalling	 causes	 its	 activation	 to	 a	 high	
affinity	 form	 (Gaul	 et	al.	 2015).	 The	 signalling	 leading	 to	 activation	 of	 platelet	




al.	 2002).	 At	 the	 initial	 stages	 of	 platelet	 activation	 Ca2+	 and	 DAG-regulated	
guanine	 nucleotide	 exchange	 factor	 I	 (CalDAG-GEFI)	 are	 responsible	 for	 the	
conversion	of	GDP	to	GTP.	Increase	in	the	intracellular	level	of	Ca2+	and	DAG,	in	
the	initial	phase	of	platelet	activation	leads	to	CalDAG-GEFI	activation	and	in	the	
later	 phase	 PKC/P2Y12	 signalling	 activates	 Rap1	 providing	 sustained	 platelet	
activation	and	stable	thrombus	formation	(Li	et	al.	2010).		
Outside-in	signalling		
Activated	 integrin	 αIIbβ3	 can	 bind	 to	 fibrinogen	 (Litvinov	 et	 al.	 2005),	
fibrin	 (Podolnikova	 et	 al.	 2014)	 and	 VWF	 providing	 additional	 adhesion	 and	
causes	 aggregation	 of	 platelets	 (Mehrbod	 et	 al.	 2013).	 Interaction	 of	 integrin	




Proteins	 that	 bind	 directly	 to	 the	 cytoplasmic	 domains	 of	 αIIbβ3	 include	 β3-
endonexin,	CIB1,	talin,	kindlin,	myosin,	Shc	and	the	tyrosine	kinases	Src,	Fyn	and	
Syk	(Zhi	et	al.	2015b).	The	change	in	conformation	of	the	cytoplasmic	domain	of	
αIIbβ3	 results	 in	 exposure	of	 the	 tyrosine	 sites,	which	get	phosphorylated	and	
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provide	the	site	 for	binding	of	signalling	cascade	proteins	(Jenkins	et	al.	1998).	
Ligand	 binding	 to	 αIIbβ3	 results	 in	 phosphorylation	 of	 cytoplasmic	 domain	 of	
FcγRIIa	 and	 inhibition	 of	 this	 phenomenon	 results	 in	 inactivation	 of	
amplification	 signalling	 during	 platelet	 activation	 (Boylan	 et	 al.	 2008).	
Phosphorylation	 of	 FcγRIIa	 results	 in	 activation	 of	 Syk,	 which	 subsequently	
activates	phospholipase	C	 -	 γ2	 (PLCγ2).	Phospholipase	C	 (PL-C)	plays	a	 role	 in	
release	of	calcium	from	the	intracellular	stores	into	the	platelet	cytosol.	PL-C	acts	
on	 membrane	 bound	 polyphosphoinositide	 (PI)4,5P2	 converting	 it	 to	
diacyglycerol	 (DAG)	 and	 inositol	 1,4,5	 triphosphate	 (IP3).	 IP3	 exists	 in	 soluble	
form	 in	 the	 cytosol	 that	 binds	 to	 receptors	 on	 dense	 membrane	 system	 in	
platelets	 and	 causes	 release	 of	 intracellular	 calcium	 whereas	 DAG	 causes	
activation	 of	 PKC,	 resulting	 in	 amplification	 of	 platelet	 activation	 signals	





Figure	 1.5:	 Platelet	 activation	 mechanism.	 Platelet	 activation	 by	 different	
mechanisms	 leading	 to	 granule	 secretions,	 platelet	 shape	 change	 and	 integrin	
activation.	 Signalling	 events	 indicated	 by	 arrows	 (black)	 leads	 to	 integrin	
activation.	 Collagen	 activates	 platelets	 via	 GPVI.	 PAR	 receptors	 are	 activated	 by	
thrombin,	thromboxin	A2	(TxA2)	binds	to	TPα,	ATP	binds	to	P2X1	and	ADP	to	P2Y1	
and	P2Y12	causing	amplification	of	platelet	activation	signaling.	The	lightning	sign	
indicates	outside	 in	 signalling	event	 through	activated	 integrin	αIIbβ3	 leading	 to	
complete	platelet	activation.	Stars	indicate	the	amplification	response	of	activated	











 In	 intact	 endothelium	 and	 vasculature,	 regulation	 of	 platelet	 function	 is	
essential	 in	 controlling	 hemostasis.	 In	 normal	 circulation	 platelet	 activation	 is	
inhibited	by	nitric	oxide	(NO)	and	prostacyclin	(PGI2)	(Mitchell	et	al.	2008).	
Nitric	 oxide	 –	 is	 released	 by	 non-diseased	 blood	 vessels	 and	 intact	
endothelium	 (Tousoulis	 et	 al.	 2012).	 It	 is	 antithrombotic	 and	 a	 vasodilator	
(Mitchell	 et	 al.	 2008).	 In	 platelets	 NO	 binds	 to	 soluble	 Guanyle	 cyclase	 (sGC)	
resulting	 in	 its	 conformational	 change	 that	 increases	 its	 catalytic	 activity.	
Activated	 sGC	 increases	 level	 of	 cGMP	 that	 acts	on	 cGMP	dependent	 receptors,	
cGMP	regulated	phosphodiesterases	(PDE)	and	activate	cGMP	dependent	protein	
kinases	 (Gkaliagkousi	 et	 al.	 2007).	 Increase	 in	 levels	 of	 cGMP	 decreases	
intracellular	Ca2+	levels	via	cGMP	dependent	protein	kinase	G	that	inhibits	entry	
of	 extracellular	 Ca2+	 and	 its	 release	 from	 dense	 tubular	 system	 (Geiger	 et	 al.	
1992).	 	 NO	 also	 inhibits	 αIIbβ3	 by	 directly	 regulating	 phosphorylation	 of	 β3	
(Oberprieler	 et	 al.	 2007).	 P-selectin	 expression	 is	 affected	 by	 nitric	 oxide	 via	
inhibition	 of	 PKC	 (Murohara	 et	 al.	 1995).	 Nitric	 oxide	 is	 also	 released	 upon	
platelet	activation	that	is	seen	to	be	responsible	for	auto-regulation	of	enhanced	
platelet	 function	 during	 thrombus	 formation.	 Platelets	 regulate	 the	 effect	 of	
nitric	 oxide	 by	 desensitization	 of	 NO/cGMP	 system	 and	 producing	 reactive	
oxygen	 species	 (ROS)	 through	 glutathione	 cycle	 and	 lypooxygenase	 pathway	
(Bellamy	et	al.	2000;	Friebe	&	Koesling	2003).		
Prostaglandin	 (PGI2)	 –	 is	 a	 lipid	 derived	 from	 C-20	 unsaturated	 fatty	
acid	 archidonic	 acid	 and	 is	 synthesized	 by	 the	 enzyme	 prostacyclin	 synthase,	
which	 is	 predominantly	 present	 in	 endothelial	 and	 smooth	 muscle	 cells	
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(Gryglewski	 et	al.	 1978).	 Platelets	 have	 PGI2	 receptors	 –	 IP	 receptors	 that	 are	
members	of	the	prostanoid	family	of	G-protein	coupled	receptors	(Klockenbusch	
et	al.	1996).	PGI2	on	binding	to	IP	receptors	 leads	to	series	of	signalling	events	
resulting	 in	 increase	of	cAMP	 levels	 that	causes	activation	of	phospho	kinase	A	




inhibiting	 granule	 secretion	 (Aburima	 et	al.	 2013).	 The	 balance	 between	TXA2	
and	PGI2	is	essential	for	normal	thrombotic	function.	TXA2	is	a	platelet	agonist	
and	vasoconstrictor	and	PGI2	counter	acts	these	effects.	The	PGI2	receptor	and	
TXA2	 receptor	 can	 from	 a	 heterodimer.	 This	 heterodimerization	 has	 shown	 to	
increase	the	cAMP	levels	and	lead	to	platelet	inhibition	(Gryglewski	et	al.	1978).	
1.4.	Platelets	in	the	Immune	Response	
Platelets,	mainly	 due	 their	 abundance	 in	 the	 blood	 stream,	 are	 the	 first	
cells	 to	 come	 into	 contact	 with	 a	 pathogen	 entering	 the	 blood	 (Shiraki	 et	 al.	
2004).	Along	with	the	hemostatic	function,	platelets	are	also	known	to	play	a	role	
in	 the	 immune	 and	 inflammatory	 responses	 (Weyrich	 et	 al.	 2004).	 Various	
surface	molecules	on	the	platelet	surface	play	 important	 functions	 in	 its	role	 in	
the	immune	system.	P-	selectin,	a	cell	adhesion	molecule	expressed	on	activated	
platelets	 and	 endothelial	 cells,	 is	 important	 in	 the	 initial	 recruitment	 of	
leukocytes	 in	 immune	 or	 inflammatory	 responses	 (Palabrica	 et	 al.	 1992).	 P-	
selectin	binds	 to	 the	P-	selectin	binding	glycoprotein	 ligand	1	(PSGL1)	and	this	
reversible	 interaction	 is	 important	 in	 initial	 tethering,	 rolling	 and	 subsequent	
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firm	arrest	of	 the	platelets	 (Frenette	et	al.	1995).	Thus	PSGL1	bearing	 immune	
cells	 can	 also	 bind	 to	 the	 platelets	 and	 thus	 facilitate	 in	 formation	 of	
platelet/leukocyte	 complexes	 and,	 vice	 versa,	 supporting	 leukocyte	 rolling	 and	
arrest	on	surface-adherent	platelets	(Cerletti	et	al.	2010;	Hara	et	al.	2010).		
Integrin	αIIbβ3	is	the	most	important	surface	molecule	in	the	aggregation	
of	 platelets.	 Activated	 αIIbβ3	 along	with	 fibrinogen	 and	 von	Willebrand	 factor	
can	 interact	 with	 CD40L	 triggering	 outside-in	 signaling	 (André	 et	 al.	 2002;	
Prasad	 et	 al.	 2003).	 Activated	 platelets	 are	 known	 to	 up-regulate	 the	
concentration	of	CD40L	which	 interacts	with	endothelial	cells	via	CD40	leading	
to	 increase	 in	 the	 concentration	 of	 adhesive	 molecules	 on	 their	 surface	 and	
consequently	increase	recruitment	of	immune	cells	(Dickfeld	et	al.	2001;	May	et	
al.	 2002).	 CD40	 is	 also	 present	 on	monocytes	 (Alderson	 et	al.	 1993),	 dendritic	
cells	 (Ma	 et	 al.	 2010),	 and	 B	 cells	 (Lee	 et	 al.	 2003)	 and	 contributes	 to	 the	
development	of	the	acquired	immune	response.		
Activated	 platelets	 also	 secrete	 soluble	 immune	 mediators.	 The	 first	 of	
which	to	be	identified	was	chemokine	platelet	factor	4	(PF4).	PF4	is	stored	in	α	
granules	 and	 in	 presence	 of	 TNFα	 it	 induces	 exocytosis	 and	 firm	 neutrophil	
adhesion	 to	 the	 endothelium	 (Petersen	 et	 al.	 2014).	 PF4	 interacts	 with	 other	
immune	 modulators	 and	 affects	 their	 function	 e.g.	 it	 binds	 to	 RANTES	
(Chemokine	ligand	5)	and	promotes	the	monocyte	adherence	(Hundelshausen	et	
al.	 2005).	 Thrombin	 induced	 platelet	 activation	 releases	 RANTES	 which	 is	
necessary	 for	 P-selectin	 dependent	 monocyte	 adhesion	 to	 the	 endothelium	
(Schober	et	al.	2002;	Hundelshausen	et	al.	2001).			
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Interleukin	1	 (IL1)	 is	 an	 important	 immune	and	 inflammatory	mediator	
secreted	 by	 platelets	 (Loppnow	 et	 al.	 1998).	 Platelets	 not	 only	 contain	 pre	
formed	IL1	(Loppnow	et	al.	1998;	Sedlmayr	et	al.	1995)	but	also	show	sustained	
synthesis,	controlled	at	the	translational	level,	by	activation	of	platelet	integrins	






Direct	 evidence	 of	 the	 involvement	 of	 platelets	 in	 the	 immune	 system	
comes	through	the	presence	of	toll	like	receptors.	Platelets	are	known	to	posses	
TLR1,	TLR2,	TLR4,	TLR6,	TLR8,	and	TLR9	(Blair	et	al.	2009;	Shiraki	et	al.	2004;	F	
Cognasse	 et	 al.	 2005).	 On	 activation	 by	 a	 physiological	 agonist	 (thrombin),	
expression	 of	 TLR-2	 and	 TLR-4	 is	 unchanged;	 however	 TLR-9	 is	 increased	
suggesting	 that	 TLR-9	 may	 be	 transported	 from	 intracellular	 compartments	
(Aslam	et	al.	2006).	The	exact	 function	of	TLRs	on	platelets	 is	unclear	but	 they	
are	 believed	 to	 play	 a	 role	 in	 their	 participation	 in	 immune	 and	 inflammatory	








immunity,	 and	 thrombosis.	 Platelet	 TLR-2	 has	 a	 role	 in	 platelet-	 neutrophil	
aggregate	 formation	 in	a	P-selectin	dependent	manner	(Blair	et	al.	2009).	Also,	
platelets	 aggregate	 and	 adhere	 to	 collagen	 more	 readily	 on	 treatment	 with	 a	
known	TLR-2	 ligand	Pam3CSK4	(Blair	et	al.	2009).	TLR-2	stimulation	has	been	
shown	to	activate	the	phosphoinositide	3-kinase	(PI3-K)/Akt	signaling	pathway	




(Silverstein	 &	 Febbraio	 2009).	 It	 is	 important	 in	 uptake	 of	 parasitized	
erythrocytes	by	macrophages	during	malaria	infection	(Ren	2012).	Macrophage	
CD36	is	attributed	to	many	immune	and	inflammatory	functions.	It	is	speculated	
to	 be	 involved	 in	 inflammatory	 signalling	 cascade	 by	 interacting	 with	 other	
receptors	 such	 as	 TLRs.	Macrophage	 CD36-dependent	 signalling	 is	 involved	 in	
the	 pro-inflammatory	 effects	 of	 internalizing	β-amyloid	 (Moore	 et	 al.	 2002),	
oxLDL	(Maxeiner	et	al.	1998),	and	bacteria	 (Janabi	et	al.	2000).	CD36	has	been	
shown	 to	 associate	 with	 TLR2	 in	 innate	 sensing	 and	 inducing	 inflammatory	
cytokines	 in	 response	 to	 TLR2	 agonists	 such	 as	 whole	 bacteria	 like	 S.	 aureus	
(Stuart	et	al.	2005)	and	bacterial	ligands	(Triantafilou	et	al.	2006).		
Microglia	 cell	 CD36	 on	β-amyloid	 uptake	 also	 boosts	 pro-inflammatory	
response	 and	 may	 contribute	 to	 the	 pathogenesis	 of	 Alzheimer’s	 disease	
(Silverstein	&	Febbraio	2009).	CD36	recognition	of	oxLDL	and	β-amyloid	triggers	
assembly	 of	 a	 heterotrimeric	 complex	 composed	 of	 CD36,	 TLR4	 and	 TLR6,	
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leading	 to	 the	 induction	 of	 pro-inflammatory	 mediators	 implicated	 in	 the	
harmful	effects	of	oxLDL	and	amyloid-β	in	vivo	(Stewart	et	al.	2010).	TLR2	also	
requires	CD36	for	 inflammatory	signalling	(Silverstein	&	Febbraio	2009).	CD36	
is	 necessary	 for	 the	 component	 of	 ischemic	 brain	 injury	 attributable	 to	 the	
inflammatory	 response	 triggered	 by	 TLR2/1	 activation	 (Abe	 et	 al.	2010).	 The	
inflammatory	response	 in	brain	 induced	by	TLR2/1	activation,	but	not	TLR2/6	
or	TLR4	activation,	is	suppressed	in	CD36-null	mice	(Abe	et	al.	2010).	In	contrast	
to	 brain	 inflammation,	 in	 systemic	 inflammation	 CD36	 is	 involved	 in	 TLR2/6	
activation,	but	not	TLR2/1	activation	 (Abe	et	al.	 2010;	Triantafilou	et	al.	2006;	
Hoebe	et	al.	2005).		
Role	 of	 CD36	 in	 Oxidised	 LDL	 induced	 platelet	 activation	 is	 known	
(Magwenzi	et	al.	 2015)	but	way	 in	which	 it	 responds	 to	 other	diacylglycerides	
moieties	 (specifically	 bacterial)	 is	 not	 yet	 understood.	 Significance	 of	 CD36	 in	




	 The	 S.	 aureus–platelet	 interaction	 is	 a	 complicated	 process	 involving	
multiple	 receptors	 on	 both	 cells.	 von	 Willebrand	 factor	 (vWF)	 is	 the	 major	
glycoprotein	 which	 is	 necessary	 for	 the	 adhesion	 of	 platelets	 to	 the	 damaged	
vessel	wall.	Platelets	do	not	have	an	affinity	for	the	circulating	vWF	but	can	bind	
to	immobilized	vWF	(Reininger	et	al.	2006).	S.	aureus	42kDa	surface	protein	SpA	
which	 is	made	up	 of	 five	 domains	 each	 having	 IgG	 Fc	 region	 binding	 property	
(Fosteret	et	al.	1998;	Graille	et	al.	2000)	can	also	bind	to	von	Willebrand	factor	
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aureus.	 Both	proteins	 bind	Fg	 at	 different	 domains.	 Fg	 is	 a	 large	protein	made	
from	 two	 sets	of	 three	polypeptide	 chains-	Aα,	Bβ	and	γ	 and	 thus	 is	known	as	
dimer	of	 trimers	 (Mosesson	et	al.	 2001).	 ClfA	binds	 to	 the	C-terminal	 of	 the	γ-
chain	(McDevitt	et	al.	1997)	and	ClfB	to	the	Aα	and	Bβ-	chains	(Ní	Eidhin	et	al.	
1998).	In	ClfA,	the	C-	terminus	of	its	A-chain	binds	to	Fg	and	amino	acids	Glu526	





spaces)	 and	 can	 inhibit	 the	 binding	 of	 ClfA	 to	 soluble	 Fg,	 thus	 allowing	 the	
bacteria,	under	the	right	conditions,	to	adhere	to	solid-phase	fibrinogen	or	fibrin	
clots	 (O’Connell	 et	 al.	 1998).	 Also,	 it	 has	 been	 speculated	 that	 Ca2+	 dependent	
regulation	 of	 ClfA	 binding	 to	 Fg	 may	 aid	 bacteria	 to	 detach	 from	 the	 initial	
vegetation	in	order	to	proliferate	(O’Connell	et	al.	1998).	The	interaction	of	ClfB	
with	 Fg	 is	 also	 through	 its	 A	 domain	 which	 is	 composed	 of	 sub	 domains:	 N1	
which	 is	 elongated,	N2,	N3	 and	N23-	which	 are	 globular	 (Perkins	 et	al.	 2001).	
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Cleavage	of	the	N1	sub	domain	changes	the	ability	of	ClfB	to	bind	the	Fg.	During	
the	 stationary	 phase	 of	 its	 growth	 S.	 aureus	 expresses	 the	 metalloprotease	
aureolysin	 which	 cleaves	 the	 N1	 subdomain	 of	 ClfB	 (McAleese	 et	 al.	 2001),	
changing	 the	 ability	 of	 ClfB	 to	 bind	 the	 Fg.	 The	 proportion	 of	 truncated	 ClfB	
increases	 as	 the	S.	aureus	 culture	 grows	 and	 the	 Fg	 –	 binding	 ability	 of	 ClfB	 is	
substantially	 reduced	 in	 stationary	 phase	 cells	 (McAleese	 et	 al.	 2001)	 thus	 it	
shows	the	regulated	ClfB	binding	(Perkins	et	al.	2001;	Clarke	et	al.	2006).	
By	studying	mutants	of	S.	aureus	that	lacked	one	or	more	surface	proteins	
and	 by	 expressing	 such	 surface	 protein	 individually	 on	 the	 surface	 of	 the	
surrogate	Gram-positive	host	bacterium	Lactococcus	lactis,	clumping	factors	(Clf)	
A	and	B	were	seen	to	cause	activation	of	human	platelets	in	plasma,	of	which	ClfA	
is	 the	 more	 potent	 (L.	 O’Brien	 et	 al.	 2002).	 Platelet	 activation	 through	 ClfA	
requires	 the	 presence	 of	 ClfA	 specific	 IgG	 and	 can	 occur	 with	 or	 without	 the	
fibrinogen	 bridge	 (Loughman	 et	 al.	 2005).	 	 Fibrinogen-dependent	 platelet	
activation	requires	binding	of	ClfA	with	fibrinogen	and	the	presence	of	IgG	which	
interacts	 with	 platelet	 Fc	 receptor	 FcγRIIa	 on	 the	 platelets.	 Fibrinogen-
independent	platelet	activation	requires	binding	of	 IgG	to	ClfA	and	assembly	of	
complement	 proteins,	 interacting	 with	 FcγRIIa	 and	 a	 complement	 receptor	
respectively	on	the	platelet	surface	(Loughman	et	al.	2005).		
Fibronectin-binding	 proteins,	 FnBPA	 and	 FnBPB	 are	 major	 platelet	
activating	 factors	 on	 the	 surface	 of	 S.	 aureus	 from	 the	 exponential	 phase	 of	
growth	 (Fitzgerald	 et	 al.	 2006).	 FnBPA	 and	 FnBPB	 are	 structurally	 identical,	
being	 composed	 of	 four	 (A,	 B,	 C	 and	 D)	 domains	 consisting	 two	 and	 four	
repeating	sequences	of	B	and	D	domain	respectively	(Foster	et	al.	1998;	Penkett	
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and	 fibrinogen	bridges	 that	bind	 to	 the	 low	affinity	 form	of	αIIbβ3	on	platelets	
(Fitzgerald	 et	al.	 2006).	 Also	 another	way	 of	 FnBPA	 interaction	 is	 through	 IgG	
reactive	 to	 FnBPA	 D-domain	 and	 A-	 domain,	 which	 engages	 with	 platelet	 Fc	
receptor	 FcγRIIa.	 These	 interactions	 of	 FnBPA	 with	 platelets	 led	 to	 platelet	
activation	(Fitzgerald	et	al.	2006).	
Another	 surface	 protein	 on	 the	 S.	 aureus	 surface,	 which	 is	 expressed	
under	 low	 iron	 conditions	 (typically	 a	 marker	 of	 in	 vivo	 conditions),	 the	 iron	
regulated	 surface	 determinant	 (Isd)	 proteins.	 One	 of	 these:	 IsdB	 can	 directly	
interact	 with	 the	 platelet	 integrin	 GPIIb/IIIa	 (Miajlovic	 et	 al.	 2010),	 triggering	
their	activation.	Serine-aspartate	repeat	proteins	(Sdr)	have	structural	similarity	
with	ClfA	and	ClfB	(Josefsson	et	al.	1998).	SdrE	activates	the	platelets	with	longer	
aggregation	 lag	 time	 than	 that	 observed	 for	 other	 adhesions	 (L.	 O’Brien	 et	 al.	
2002).	 Longer	 lag	 time	 indicates	 that	 the	 interaction	 of	 SdrE	 with	 its	 platelet	
receptor	 is	 relatively	weak	 and	 requires	 a	 longer	 period	 of	 time	 to	 trigger	 the	
aggregation	process	(L.	O’Brien	et	al.	2002).	SraP	is	a	glycoprotein	located	on	the	
surface	 of	 S.	 aureus,	 which	 prevalent	 in	 clinical	 isolates	 and	 is	 associated	




S.	aureus	 secreted	 α-toxin	 activates	 platelets	 either	 directly	 (Hugo	 et	al.	
1988;	Schubert	et	al.	2011)	or	indirectly	(Bayer	et	al.	1997).	In	human	platelets,	
α-toxin	 is	 thought	 to	 stimulate	 activation	 by	 production	 of	 a	 prothrombinase	
complex	 on	 the	 platelet	 surface,	 which	 converts	 prothrombin	 to	 thrombin	
(Hemker	et	al.	1967),	a	potent	inducer	of	activation	in	platelets	(Vu	et	al.	1991).	
This	occurs	via	two	mechanisms.	Firstly	the	attack	of	α-toxin	causes	the	release	
of	 factor	 five	 (FV)	 stored	within	 the	α-	 granules	 of	 human	platelets,	which	 are	
released	upon	platelet	stimulation	by	agonists	such	as	thrombin	and	collagen.	FV	
is	then	converted	to	factor	five	a	(FVa)	by	thrombin.	Both	FV	and	FV(a)	promote	
the	 assembly	 of	 a	 prothrombinase	 complex	 on	 the	 cell	 surface	 (Arvand	 et	 al.	
1990).	 Secondly	 α-toxin	 directly	 acts	 by	 producing	 lesions	 on	 the	 cell	 surface,	
which	 produces	 an	 influx	 of	 calcium	 ions.	 These	 lesions	 alter	 the	 cell	 surface	
promoting	 the	 production	 of	 the	 prothrombinase	 complex	 in	 an	 exocytosis	
independent	manner	 (Arvand	 et	 al.	 1990).	 α-toxin	 also	 stimulates	 the	 arterial	
endothelial	cells	to	synthesize	the	Platelet	Activating	Factors	(PAF)	(Bayer	et	al.	
1997)	 thus	 promoting	 platelet	 activation.	 Other	 secreted	 products	 of	 S.	aureus	
contributing	to	platelet	activation	are	the	two	prothrombin	activating	molecules,	
staphylocoagulase	 and	 von	 Willebrand	 factor-binding	 protein	 (vWbp),	 which	
combine	 with	 prothrombin	 and	 form	 the	 staphylothrombin	 complex.	 The	
staphylothrombin	 complex	 has	 the	 ability	 to	 convert	 fibrinogen	 to	 fibrin	 and	
contribute	to	platelet	activation	(Vanassche	et	al.	2011).			
In	addition	to	activators	of	platelets,	multiple	S.	aureus	components	have	
the	 ability	 to	 inhibit	 them.	 S.	 aureus	 LTA	 interacts	with	 platelet	 PafR	 receptor	
causing	increase	in	cAMP	level	thus	resulting	in	inhibition	of	platelet	activation	
(Waller	 et	 al.	 2013).	 Inhibition	 of	 platelet	 function	 by	 the	 S.	 aureus	 LTA	 is	
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attributed	 to	 its	 ability	 to	 evade	 the	 immune	 system	 as	 this	 interaction	 also	
inhibits	 platelet-dependent	 inflammatory	 mediator	 release	 and	 platelet-
monocyte	 aggregation	 (Wu	 et	 al.	 2011).	 S.	 aureus	 also	 produces	 and	 secretes	
extracellular	 fibrinogen	 binding	 protein	 (Efb)	 which	 can	 inhibit	 platelet	
activation	 (Shannon	 et	 al.	 2004).	 Efb	 can	 bind	 platelets	 directly	 or	 through	
fibrinogen.	Both	of	these	interactions	are	proposed	to	inhibit	platelet	activation	




mediated	 immune	 functions	 (Ramsland	 et	 al.	 2011).	 	 FcγRIIa	 in	 platelets	 is	
significant	in	amplification	of	outside	in	signalling	occurring	via	αIIbβ3	(Boylan	
et	al.	 2008).	 It	 plays	 significant	 role	 in	 bacteria	mediated	 platelet	 activation	 in	
synergism	 with	 integrin	 αIIbβ3	 (Arman	 et	 al.	 2014).	 Direct	 cross	 linking	 of	
FcγRIIa	 receptor	 leads	 to	 phosphorylation	 of	 tyrosine	 residues	 in	 its	




(Fitzgerald	et	al.	 2006).	 Platelet	 activation	on	direct	 cross	 linking	 of	 FcγRIIa	 is	
independent	of	integrin	αIIbβ3	engagement,	but	in	the	case	of	bacteria	mediated	
platelet	 activation,	phosphorylation	of	FcγRIIa	 is	dependent	on	 integrin	αIIbβ3	
engagement	 (Arman	 et	 al.	 2014).	 Binding	 of	 IgG	 against	 bacterial	 antigen	 to	
FcγRIIa	 does	 not	 lead	 to	 sufficient	 stimulus	 to	 cause	 platelet	 activation,	 in	
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addition	 to	 that	 it	 requires	 feedback	 signal	 from	 engagement	with	 αIIbβ3	 and	
granule	 release	 (Arman	 et	al.	 2014).	 In	 the	 case	 of	S.	aureus	 it	might	 occur	 on	
binding	 of	 ClfA/B	 with	 αIIbβ3	 via	 fibrinogen	 bridge	 (McDevitt	 et	 al.	 1997;	 Ní	
Eidhin	 et	 al.	 1998).	 The	 engagement	 of	 αIIbβ3	 and	 FcγRIIa	 causes	 weak	
signalling	response	that	leads	to	release	of	granules	that	reinforces	the	activation	
signalling	 resulting	 in	 platelet	 activation	 and	 aggregation	 (Arman	 et	al.	 2014).	
Thus	under	arterial	shear	condition	 interaction	between	 IgG	and	FcγRIIa	along	
with	 engagement	 of	 integrin	 αIIbβ3	 and	 granule	 release	 is	 thought	 to	 be	 of	















is	 induced	 by	 toxins	 and	 proteins	 released	 by	S.	 aureus.	 B.	 Interactions	 between	








to	 the	 membrane	 (Nakayama	 et	 al.	 2012).	 Bacterial	 lipoproteins	 have	 been	
attributed	 with	 many	 functions	 like	 sensing	 (chemoreception)	 and	 signalling	
(initiate	 sporulation),	 protein	 secretion,	 antibiotic	 resistance,	 adhesion	 and	
uptake	 of	many	 nutrients	 and	 ions	 (Sutcliffe	 et	al.	 1995).	 They	 have	 also	 been	
shown	to	play	roles	in	virulence	by	supporting	colonization,	invasion,	evasion	of	
host	defence	and	 immune	modulation	 (Kovacs-Simon	et	al.	 2011;	Nakayama	et	
al.	 2012).	 Bacterial	 lipoproteins	 play	 roles	 in	 induction	 of	 macrophages	
(Brightbill	 et	 al.	 1999),	 dendritic	 cell	 maturation	 (Hertz	 et	 al.	 2001),	 cytokine	
production	(Kreutz	et	al.	1997)	and	activation	of	B-	Lymphocytes	(Bessler	et	al.	
1985).	 It	 is	 clearly	 evident	 through	 a	 number	 of	 studies	 that	 the	 bacterial	










(Stoll	 et	 al.	 2005).	 	 Lipoproteins	 are	 synthesized	 (Figure	 1.6)	 as	 pre-




by	 the	 lipoprotein	 diacylglyceryl	 transferase	 (Lgt)	 (Qi	 et	 al.	 1995).	 The	 signal	
peptide	 of	 the	 prolipoprotein	 is	 cleaved	 by	 the	 lipoprotein	 signal	 peptidase	
(LspA)	(Qi	et	al.	1995).	While	in	Gram-negative	bacteria	lipoproteins	are	further	
modified	at	the	diacylglyceryl-cysteine	by	N-acyltransferase	(Lnt)	(Kovacs-Simon	
et	 al.	 2011),	 a	 homolog	 of	 Lnt	 has	 not	 been	 identified	 in	 S.	 aureus	 (Stoll	 et	 al.	
2005),	suggesting	that	S.	aureus	lipoproteins	are	diacylated.		
S.	 aureus	 lipoproteins	 are	 essential	 for	 recognition	 of	 bacteria	 by	 the	
immune	 system	 (Bubeck	 Wardenburg	 et	 al.	 2006).	 S.	 aureus	 lgt	 (lacking	
lipoproteins)	 is	not	efficiently	recognized	by	 immune	cells	(Stoll	et	al.	2005).	S.	
aureus	 lipoproteins	 are	 capable	 of	 interacting	 with	 macrophages	 (Kim	 et	 al.	
2015),	human	coronial	epithelial	cells	(Li	et	al.	2008)	and	murine	keratinocytes	
(Müller	 et	 al.	 2010).	 TLR2	 is	 found	 to	 be	 the	 major	 receptor	 for	 S.	 aureus	




































Figure	 1.7:	 Biosynthesis	 of	 bacterial	 lipoproteins.	 Two-step	 biosynthetic	
pathway	in	Gram-positive	bacteria	and	three-step	biosynthetic	pathway	in	the	case	
of	Gram-negative	bacteria.	The	precursor	of	 lipoproteins	 is	 the	preprolipoprotein,	
with	an	N-terminal	signal	peptide	possessing	a	characteristic	consensus	sequence	
of	 the	 lipobox.	 During	 lipoprotein	 maturation,	 the	 thiol	 group	 of	 the	 invariant	
cysteine	 in	 the	 lipobox	 is	 modified	 by	 a	 diacylglyceryl	 moiety	 by	 lipoprotein	
diacylglyceryl	 transferase	 (Lgt),	 which	 serves	 as	 a	 membrane	 anchor.	 After	
lipidation,	lipoprotein	signal	peptidase	(Lsp)	cleaves	the	signal	peptide,	leaving	the	
cysteine	 as	 the	 new	 amino-terminal	 residue	 forming	 the	 mature	 lipoprotein	 in	





	 With	 its	 varied	 strategies	 to	 survive	 in	 its	 host,	 S.	 aureus	 is	 a	 major	
pathogen	causing	diseases	which	range	from	moderate	skin	infections	(Kintarak	
et	 al.	 2004)	 to	 severe	 life	 threatening	 invasive	 conditions	 like	 endocarditis	
(Naber	2009).	The	ability	of	S.	aureus	to	modulate	platelet	function	is	speculated	
to	 be	 significant	 in	 bacterial	 endocarditis	 (Ganesh	 et	 al.	 2008)	 and	 delayed	
wound	healing	(Shannon	&	Flock	2004).	Most	of	the	S.	aureus	surface	(L.	O’Brien	
et	al.	 2002;	 Siboo	 et	al.	 2005;	 Fitzgerald,	 Loughman,	 et	al.	 2006)	 and	 secreted	
(Shannon	&	Flock	2004;	Waller	et	al.	2013)	molecules	that	can	modulate	platelet	
functions	have	been	studied	in	an	attempt	to	understand	the	pathology	behind	S.	
aureus-platelet	 interaction.	 But	 the	 role	 of	 S.	 aureus	 lipoproteins	 in	 this	
interaction	is	as	yet	unknown.		
S.	 aureus	 lipoproteins	 are	 set	 of	 surface	 components	 essential	 for	
eradication	 of	 S.	 aureus	 infection	 by	 the	 host	 immune	 system	 (Bubeck	
Wardenburg	et	al.	2006).	The	ability	of	host	immune	cells	to	recognize	S.	aureus	
lipoproteins	has	made	them	prime	target	for	vaccine	discovery	against	S.	aureus	
infections	 (Anderson	 et	 al.	 2012).	 Platelets	 contribute	 the	 the	 immune	 and	
inflammatory	 response	 (von	 Hundelshausen	 &	 Weber	 2007)	 and	 express	
receptors	 known	 for	 their	 immune	 function	 (Aslam	 et	 al.	 2006).	 Toll	 like	
receptors	and	scavenger	receptors	are	present	on	platelet	surface	that	recognize	
lipoproteins	 (Valiyaveettil	 &	 Podrez	 2009).	 Synthetic	 lipoproteins	 like	




Thus	 the	 aims	 of	 this	 project	 were,	 firstly	 to	 evaluate	 the	 ability	 of	 S.	



























Chemicals	were	 obtained	 from	 Sigma	 (Poole,	 UK),	 Acros	 organics	 (Geel,	





Collagen	 was	 obtained	 from	 Nycomed	 (Munich,	 Germany),	 bovine	






(Kidderminster,	 UK).	 Gel	 electrophoresis	 equipment	was	 from	BioRad.	 Protein	
markers	were	obtained	from	Thermo	Scientific.		
2.1.5.	Western	blotting	materials		




chemiluminescence	 (ECL)	 and	 Sigma	 fast	 alkaline	 phosphatase	 was	 obtained	
from	Thermo	Scientific	Pierce	and	Sigma	respectively.		
2.1.6.	Western	blotting	antibodies	
Secondary	 HRP	 and	 alkaline	 phosphatase	 conjugated	 anti-mouse,	 anti-
rabbit,	 anti-goat	 and	 anti-human	 antibodies	 were	 obtained	 from	 Sigma.	 Other	
antibodies	are	detailed	in	Table	2.13.	
2.1.7.	Co-precipitation	assay	materials	















(OD600)	 was	 0.1	 and	 was	 transferred	 to	 detergent	 free,	 sterile	 100	 ml	 flask.	
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Sterile	 phage	 buffer	 (100	ml)	 (Table	 2.1)	 and	 100	 μl	 of	 stock	 lysate	 (phage	 –	
ϕ85)	was	added.	The	suspension	was	 incubated	 for	10	min	at	22oC,	 later	 for	4	
hrs	at	30oC	and	 finally	at	22oC	until	a	clear	 lysate	was	 formed	which	was	 filter	







tubes	 were	 incubated	 in	 a	 37oC	water	 bath	 for	 25	min	 and	 then	 in	 a	 shaking	









peeling	 back	 the	 top	 agar	 and	 streaked	 on	 to	 agar	 plates	 with	 respective	
antibiotics	and	incubated	at	37oC	overnight.	A	single	colony	from	plates	was	then	






medium	 and	 incubated	 at	 37oC	 for	 16	 hrs	 with	 shaking.	 Pre-warmed	 100	 ml	
chelex	 treated	 BHI	 medium	 was	 inoculated	 and	 grown	 until	 late-exponential	
phase	 (OD600–	 1)	 at	 37oC	 with	 shaking.	 Using	 these	 cultures	 100ml	 of	 pre	











transferred	 to	eppendrof	 tubes.	The	 tubes	were	centrifuged	at	8000	x	g	 for	10	
min	 to	 obtain	 the	 native	 cell	 envelopes	 (Clarke	 et	 al.	 2002).	 The	 isolated	 cell	
envelope	were	lyophilized	and	used	for	the	assays.		
2.2.4.	Lipoprotein	isolation	(TX-114	phase	partitioning	method)	
S.	 aureus	 grown	 in	 chelex	 treated	 BHI	 to	 the	 mid	 log	 phase	 was	
centrifuged	 and	 the	 pellet	 was	 resuspended	 in	 4	 ml	 1	 M	 NaCl.	 Cells	 were	
transferred	 to	 FastPrep	 tubes	 (MP	 Biomedical)	 for	 disruption	 at	 2000	
oscillations/min	 for	 7	 min.	 Glass	 beads	 were	 allowed	 to	 settle	 and	 the	 liquid	
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portion	was	 transferred	 to	 a	new	 tube.	After	 centrifugation	 at	 2000	 x	 g	 for	10	
min	supernatant	was	collected	in	a	new	tube	and	again	centrifuged	at	10000	x	g	












was	 performed	 according	 to	 institutional	 guidelines	 and	was	 approved	 by	 the	
Institutional	 Ethics	 Committee.	 Written	 consent	 was	 obtained	 from	 all	 of	 the	
donors.	 45	 ml	 blood	 in	 5	 ml	 of	 4%	 sodium	 citrate	 was	 taken.	 Blood	 was	










added	 and	 the	 concentration	 of	 platelets	was	 calculated	 using	 Coulter	 counter	
(Beckman	Coulter,	USA),	 for	which	2	μl	of	platelets	 in	10	ml	of	 isoton	 solution	
was	 used.	 Platelet	 suspension	was	 then	 centrifuged	 for	 10	min	 at	 1413	 x	 g	 at	













into	 5ml	 Chelex	 BHI	 and	 grown	 at	 37oC	 with	 shaking	 until	 OD600	 reached	 3.	
Bacteria	 were	 washed	 three	 times	 in	 Tyrodes	 buffer	 and	 finally	 OD600	 was	
adjusted	 to	 1	 in	 Tyrodes	 buffer	 which	 equals	 to	 concentration	 of	 6	 x	 108	
bacteria/ml.	Platelet	poor	plasma	(PPP)	was	used	as	blank	for	PRP	and	Tyrodes	














Washed	 human	 platelets	were	 prepared	 as	 described	 above.	Washed	 platelets	




wells	and	 incubated	 for	1	hr.	 	S.	aureus	wild	 type	and	mutant	bacteria	cultures	
were	grown	till	mid	log	phase	in	BHI	and	were	washed	three	times	with	tyrodes	
buffer	using	centrifugation	at	209	x	g	for	10	min	at	4oC	and	the	final	OD600	was	
adjusted	 to	 1.	 	 Bacteria	were	 diluted	 1:10	 v/v	 in	 tyrodes	 buffer	 before	 adding	
100	μl	to	each	well	of	the	platelet-coated	plate.	After	incubation	of	plates	at	4oC	
for	 2	 hrs	 the	 wells	 were	 washed	 three	 times	 with	 tyrodes	 buffer	 to	 remove	
unbound	bacteria.	Bound	bacteria	were	 removed	 into	100	μl	of	 tyrodes	buffer.	
Serial	 dilutions	 were	 prepared	 and	 spread	 onto	 BHI	 plates,	 which	 were	
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incubated	for	16	hrs	at	37oC.	The	number	of	bacteria	was	counted	on	each	plate	
and	percentage	binding	 to	 platelets	was	 calculated	by	 subtracting	platelet	 free	
controls	and	dividing	by	total	bacteria	added.			
2.4.3.	Flow-cytometry	
Two	sets	of	 clean	eppendorf	 tubes	were	prepared	and	 labeled	as	EGTA,	
resting,	 agonist	 controls	 and	 agonist	 plus	 samples	 (S.	 aureus	 lipoproteins)	 at	
different	 concentration.	 HEPES	 buffer	 (Table	 2.10)	 was	 added	 to	 tubes	 at	 a	
volume	such	that	on	addition	of	all	solutions	final	volume	reaches	to	50	μl.	GPRP	
and	EGTA	were	added	to	appropriate	tubes.	S.	aureus	lipoproteins	were	added	at	




prior	 to	 the	 addition	 of	 S.	 aureus	 lipoproteins.	 The	 agonist	 was	 added	 at	
appropriate	 concentrations	 and	 incubated	 for	 20	 min	 at	 room	 temperature	
before	 450	 μl	 of	 0.2%	 formaldehyde	was	 added	 to	 stop	 the	 reaction.	 In	 FACS	
tubes	 with	 450	 μl	 of	 0.2%	 formaldehyde,	 50	 μl	 of	 the	 sample	 was	 added	 in	
relevant	 tube	 and	 run	 through	 flowcytometer	 (BD	 AccuriTM	 C6	 cytometer).	
During	 analysis	 the	 platelets	were	 gated	 on	 the	 basis	 of	 size	 and	 5000	 events	









platelets	 were	 prepared	 at	 a	 concentration	 of	 2	 x	 105	 cells/ml	 and	 were	
incubated	with	different	concentrations	of	 lipoproteins.	After	 incubation	 for	15	
min	 at	37OC,	 200	μl	 of	 the	platelet-lipoprotein	mixture	was	 added	 to	 the	wells	
with	 fibrinogen	 coated	 coverslips	 and	 incubated	 for	 30,	 45	 and	 60	 min	 time	
points	 at	 37OC	 before	 washing	 twice	 with	 tyrodes	 buffer.	 After	 washing	









Fura-2	 was	 added	 to	 final	 concentration	 of	 2	 μM	 in	 PRP	 and	 was	
protected	 from	 light.	After	 incubation	at	30OC	 for	1	hour	by	 inverting	every	15	
min	 this	mixture	was	 centrifuged	at	350	x	 g	 for	20	min	 and	 the	platelet	pellet	










Preparation	 of	 cellix	 slide:	 Collagen	 at	 400	 μg/ml	 was	 injected	 at	 one	 end	
(which	was	 labeled	to	point	out	 the	end	used	to	 load	the	collagen)	of	 the	cellix	
capillary	 such	 that	 a	 quarter	 of	 capillary	 surface	 area	was	 covered.	 Each	 slide	
was	incubated	for	an	hour	at	room	temperature	and	20	μl	of	1%	BSA	was	added	
from	 the	 opposite	 side	 of	 the	 capillary.	 On	 incubation	 for	 an	 hour	 at	 room	
temperature	 the	 capillaries	were	 filled	with	 100	 μl	 of	 tyrodes	 buffer	 from	 the	
same	side	as	the	collagen	was	added.		
Thrombus	Under	flow	assay:	Whole	human	citrated	blood	was	incubated	with	
S.	 aureus	 membrane	 protein	 extracts	 for	 20	 min.	 After	 incubation,	 3,3-	
dihexyloxacarbocyanine	 iodide	 (DIOC6)	 (100	 μg/mL	 of	 whole	 blood)	 dye	 was	
added	 and	 perfused	 through	 collagen-coated	 (400	 μg/mL)	 Vena8TMBiochip	







All	 small	 SDS-PAGE	 gels	 were	 prepared	 using	 a	 Mini	 –	 Protein	
Electrophoresis	System	(BioRad,	UK)	and	large	SDS-PAGE	gels	using	the	Protein	
–	 II	 xi	 system	 (BioRad,	 UK).	 All	 buffers	 and	 gel	 solutions	 were	 prepared	 as	
described	in	Table	2.5.	For	electrophoresis	small	gels	were	run	at	125	volts	for	2	





















washed	 with	 ethanol	 and	 care	 was	 taken	 during	 procedure	 to	 avoid	 keratin	
contamination.	Desired	bands	were	cut	and	placed	in	eppendorf	tube	to	be	sent	
for	 mass	 spectrometry	 analysis	 at	 Advanced	 Mass	 Spectrometry	 Facility,	
University	 of	 Birmingham.	 The	 analysis	 was	 reported	 to	 be	 done	 on	 Orbitrap	




db.org/)	 (Jensen	 et	 al.	 2009)	 for	 identification	 of	 protein-protein	 interactions.	
For	 identification	 of	 network	 all	 the	 parameter	 like	 experimental	 repositories,	
computational	prediction	methods	and	public	text	collections	were	chosen.	The	









to	 the	membrane.	 Another	 three	 filter	 papers	 soaked	 in	western	 blot	 transfer	
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buffer	were	placed	on	to	the	gel	creating	a	sandwich	and	a	voltage	of	15	for	2	hrs	
was	 applied	 for	 blotting.	 The	 membrane	 was	 blocked	 with	 5%	 BSA	 solution	
overnight	 at	 4oC.	 After	 blocking	 a	 specific	 primary	 antibody	 was	 added	 and	
incubated	as	instructed	by	manufacturer.	The	membrane	was	then	washed	three	
times	 with	 TBS-T	 (Table	 2.8)	 for	 10	 min	 each	 time	 and	 incubated	 with	 a	
secondary	 antibody	 (1:4000)	 for	 1	 hour	 at	 room	 temperature.	 After	 washing	
three	 times	with	 TBS-T	 for	 10	min,	 depending	 on	 the	 secondary	 antibody,	 the	
blot	was	developed	using	Sigma	alkaline	phosphatase	or	by	ECL.				
2.5.8.	Co-	precipitation	assay	
Washed	 platelets	 at	 8	 X	 108	 cells/ml	 were	 placed	 in	 aggregometry	
cuvettes	and	lysed	by	NP40	lysis	buffer	(Table	2.11)	and	immediately	placed	on	
ice.	 The	 lysed	 platelet	 suspension	 was	 centrifuged	 at	 10000	 x	 g	 for	 2	 min	 to	
remove	 cytoskeleton	 proteins.	 The	 supernatant	 was	 collected	 into	 fresh	 tubes	
and	 washed	 12.5	 μl	 streptavidin	 beads	 or	 protein	 A/G	 magnetic	 beads	 were	
added	as	a	pre-clearing	step	to	remove	nonspecific	binding.	Beads	were	removed	
by	a	magnet	and	 the	platelet	 lysate	suspension	was	collected	 into	a	 fresh	 tube.	
Biotinylated	S.	aureus	lipoproteins	at	concentration	of	10	μg/ml	or	antibodies	for	
the	 specific	protein	 to	be	 co-precipitated	 (Table	2.12)	were	added	and	 tyrodes	
















































Tryptone		 10	g	 Tryptone		 10	g	
Yeast	extract		 5	g	 Yeast	extract		 5	g	
NaCl			 10	g	 KCL		 10	g	





MgSO4	 1 mM  	
CaCl2	 4 mM 	




























Tris			 9.68	g		 Tris	(pH-7.5)	 50	mM	
NaCl			 32	g		 NaCl	 0.1	M	
KCl			 0.2	g		 PMSF	 0.5	mM	










































1M	tris/HCl	(pH	6.8)		 2.5	ml	 Tris	base	 124	mM		
Glycerol			 4	ml	 Glycine	 960	mM		












Coomassie	Blue	R-250	 0.1%	 Glacial	Acetic	Acid	 10%	
Glacial	Acetic	acid	 10%	 Methanol	 45%	










Nanopure	water	 50%	 Sodium	acetate	 17	g	
























Tris			 9.68	g		 Tris			 5.82	g		
NaCl			 32	g		 SDS			 0.375	g		
KCl			 0.2	g		 Glycine		 2.93	g		
Tween	20		 0.5	mL	 Methanol		 200	mL		
















































































NaCl	 137	mM	 NP40	 1%	
KCl	 2.7	mM	 NaCl	 150	mM	









































































































































































































































S.	 aureus	 modulates	 platelet	 function	 via	 multiple	 surface	 and	
extracellular	 molecules	 that	 can	 directly	 or	 indirectly	 interact	 with	 platelet	
surface	receptors	(O’Brien	et	al.	2002;	Fitzgerald,	Foster,	et	al.	2006;	Fitzgerald,	
Loughman,	et	al.	 2006;	Waller	et	al.	 2013;	 Shannon	&	Flock	2004).	 In	order	 to	
affect	 platelet	 function	 via	 surface	 molecules,	 S.	 aureus	 needs	 to	 be	 in	 close	
proximity	 to	 bind	 platelets	 (Siboo	 et	 al.	 2005)	 to	 perturb	 normal	 platelet	








interaction	 of	 synthetic	 lipoproteins	 with	 platelet	 TLRs	 (Blair	 et	 al.	 2009;	
Kälvegren	 et	al.	 2010;	 Rivadeneyra	 et	al.	 2014)	 	 or	 on	 interaction	 of	modified	
lipoproteins	 with	 scavenger	 receptors	 (Valiyaveettil,	 Kar,	 Ashraf,	 Byzova,	
Febbraio	&	E.	a	Podrez	2008;	Magwenzi	et	al.	2015).	Given	that	lipoproteins	can	
modulate	 the	 function	 of	 human	 platelets,	 the	 experiments	 described	 in	 the	








2009).	After	 these	 structural	 changes,	 platelets	 can	bind	 to	 each	other	directly	
(Hartwig	 &	 DeSisto	 1991)	 or	 via	 plasma	 proteins	 (Ikeda	 et	 al.	 1991)	 to	 form	
aggregates.	 Measurement	 of	 platelet	 aggregation	 is	 an	 important	 marker	 in	
understanding	the	effect	of	molecules	on	platelet	function.	
Platelet	aggregations	were	carried	out	with	whole	S.	aureus	SH1000	cells	
(Figure	3.1-A,B,C)	 	and	cell	wall	extracts	(Figure	3.2-A,B,C)	of	wild	 type	and	 lgt	
strains,	 grown	 in	 chelex	 treated	 BHI	 which	 has	 low	 ion	 concentrations	
(Horsburgh	 et	 al.	 2001).	 The	 depletion	 of	 ions	 from	 the	 media	 up	 regulates	
expression	 of	 ion	 transport	 systems	 and	 most	 of	 the	 lipoproteins	 are	 part	 of	




wild	 type	 (Stoll	 et	 al.	 2005)	 (Figure	 3.3).	 S.	 aureus	 lgt	 lacks	 the	
glyceryltransferase	 enzyme	which	 is	 involved	 in	 the	 first	 step	 of	 the	 common	
biosynthetic	pathway	for	lipoproteins	(Sankaran	et	al.	1994),	thus	it	is	deficient	
in	 all	 lipoproteins	 (Stoll	 et	 al.	 2005).	 The	 growth	 phase	 of	 the	 mutant	 was	
matched	 with	 the	 wild	 type	 by	 increasing	 its	 incubation	 time.	 S.	 aureus	 lgt	
showed	 reduced	 ability	 to	 aggregate	 (Figure	 3.1A,	 C)	 the	 platelets	 and	 its	 cell	
wall	extracts	showed	significantly	 longer	aggregation	 lag	 time	compared	to	 the	
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parental	strain	(Figure	3.2B,	C).	Lipotechioc	acid	(LTA)	deficient	S.	aureus	strains	
were	 not	 considered	 for	 aggregation	 assays,	 as	 LTA	 on	 surface	 did	 not	 affect	




	 Phase	 extraction	 of	 S.	 aureus	 membrane	 proteins	 by	 the	 Triton-X	 114	
method	was	 carried	 out	 (Figure	 3.4A).	 TX-114	 is	 a	 non	 ionic	 detergent	which	
forms	a	clear	micellar	solution	in	water	at	4OC	but	increased	temperature	results	
in	 its	separation	 into	 two	phases,	detergent	and	aqueous	(Sánchez-Ferrer	et	al.	
1989).	 When	 a	 suspension	 of	 hydrophobic	 and	 hydrophilic	 substances	 is	
solubilized	 in	 TX-114	 and	 then	 allowed	 to	 separate	 in	 two	 phases,	 the	
hydrophobic	moieties	 are	 present	 in	 detergent	 phase	whereas	 the	 hydrophilic	
ones	 in	 aqueous	 phase	 (Sánchez-Ferrer	 et	 al.	 1989).	 During	 the	 extraction	 of	
membrane	proteins	 the	degraded	S.	aureus	membrane	 is	 suspended	 in	4%	TX-
114	solution	which	causes	the	hydrophobic	proteins	especially	lipoproteins	to	be	
present	 in	 the	detergent	phase	whereas	soluble	hydrophilic	portions	remain	 in	
aqueous	 phase	 (Li	 et	 al.	 2008;	 Asanuma	 et	 al.	 2011).	 By	 using	 this	 method	
membrane	proteins,	 especially	 lipoproteins	were	extracted	 from	S.	aureus	wild	
type,	S.	aureus	ΔltaS,	S.	aureus	 lgt	and	S.	aureus	ΔltaS	lgt.	(Figure	3.4A).	Western	
blot	 analysis	 of	 extracted	membrane	proteins	 from	S.	aureus	wild	 type	 and	 lgt	
strains	 showed	 the	 presence	 of	 LTA	 (Lipoteichoic	Acid)	 contamination	 (Figure	
3.4B).	S.	aureus	LTA	inhibits	platelet	activation	by	increasing	intracellular	cAMP	





Figure	3.1:	Platelet	aggregation	by	S.	 aureus	wild	 type	and	 lgt	mutants.	A.	
Data	 plotted	 as	 percent	 aggregation	 (wild	 type	 treated	 representing	 100%)	 and	
represent	mean	 values	 ±	 SEM.	B.	 Data	 plotted	 as	 lag	 time	 and	 represents	mean	
value	±	SEM.		C.	Representative	aggregation	traces	for	platelets	stimulated	with	S.	

















































envelope	 extract.	 A.	 Data	 plotted	 as	 percent	 aggregation	 (wild	 type	 treated	
representing	100%)	and	represent	mean	values	±	SEM.	B.	Data	plotted	as	lag	time	
and	 represents	 mean	 value	 ±	 SEM.	 	 C.	 Representative	 aggregation	 traces	 for	



























































































ΔltaS	 lgt	mutant	by	TX114	phase	extraction	method.	B.	Blot	 for	LTA	detection	 in	























































	 To	 evaluate	 the	 contribution	 of	 S.	 aureus	 lipoproteins	 to	 binding	 to	
platelets,	the	binding	ability	of	S.	aureus	wild	type	was	compared	with	S.	aureus	
lgt	by	a	binding	assay.	In	comparison	to	S.	aureus	wild	type,	S.	aureus	lgt	showed	





the	 ability	 of	 these	 lipoproteins	 to	 bind	 to	 platelets,	 membrane	 proteins	
extracted	 from	S.	aureus	ΔltaS	and	S.	aureus	ΔltaS	lgt	strains	were	 labeled	with	
FITC	and	their	ability	 to	bind	with	platelets	was	checked	using	 flow	cytometer.	















washed	 platelets	 were	 bound	 to	 the	 plate	 and	 bacteria	 were	 allowed	 to	 adhere.	
Adhered	bacteria	were	counted	and	percent	binding	was	calculated.	Data	plotted	
as	 percent	 binding	 and	 represent	 mean	 values	 ±	 SEM.	 B.	 Membrane	 proteins	







































































(Wardenburg	 et	 al.	 2006).	 Aggregation	 assays	 showed	 that	 the	 absence	 of	 S.	
aureus	 lipoproteins	 increases	 platelet	 aggregation	 lag	 time	 (Figure	 3.1	 –	 3.2)	
which	 is	 defined	 as	 the	 time	 taken	 to	 activate	 the	 platelets	 after	 an	 agonist	
(Pulcinelli	 et	al.	 2004),	 in	 this	 instance	 bacteria.	 It	 is	 an	 indication	 of	 the	 time	
taken	by	bacteria	to	activate	platelets	and	depends	on	two	factors;	a)	difference	
in	 affinity	 of	 different	 bacterial	 surface	molecules	 interacting	with	 platelets,	 b)	
density	 of	 adhesins	 on	 surface	 of	 the	 bacteria	 (Fitzgerald	 et	 al.	2006).	 Thus	 it	
reflects	the	contribution	of	bacterial	surface	molecules	in	the	bacteria	–	platelet	
interaction.	S.	aureus	lgt	 showed	a	 significant	 increase	 in	 lag	 time	compared	 to	
wild	 type,	 suggesting	 the	 involvement	 of	 lipoproteins	 in	 the	 interaction	 of	 S.	
aureus	with	platelets.		
Numerous	 lipoproteins	are	expressed	by	S.	aureus	 (Sheldon	&	Heinrichs	
2012).	 TX-114	 phase	 extraction	 from	 S.	 aureus	 showed	 the	 presence	 of	
numerous	 proteins	 (Figure	 3.4A).	 The	 S.	 aureus	 lgt	 strain	 which	 lacks	 the	
lipoprotein	 diacylglyceryl	 transferase	 (Lgt)	 enzyme	 essential	 for	 lipidation	 of	
pro-lipoproteins	 is	known	 to	express	prolipoproteins	on	 its	 surface	 (Stoll	et	al.	
2005).	 TX-114	 phase	 extraction	 isolates	 the	 hydrophobic	 moieties	 (Sánchez-




of	 LTA	whereas	 the	 extract	 from	S.	aureus	ΔltaS	(Corrigan	et	al.	 2011)	 did	 not	
(Figure	3.4B).	In	order	to	get	the	S.	aureus	membrane	protein	extract	that	lacked	
lipoproteins	 and	 was	 not	 contaminated	 with	 LTA,	 a	 double	 mutant	 S.	 aureus	
ΔltaS	lgt	was	constructed.	The	membrane	protein	extract	from	S.	aureus	ΔltaS	lgt	
did	not	show	any	LTA	contamination	(Figure	3.4B).	So	the	TX-114	extract	from	S.	
aureus	 ΔltaS	 and	 ΔltaS	 lgt	 double	 mutant	 were	 the	 choice	 of	 strains	 for	




the	 same	way,	S.	aureus	 direct	binding	 to	platelets	 is	 thought	 to	be	 relevant	 to	
pathogenesis	(Fitzgerald,	Loughman,	et	al.	2006;	Siboo	et	al.	2005).	Aggregation	
assays	 showed	 the	 involvement	 of	 S.	 aureus	 lipoproteins	 in	 interaction	 with	
platelets.	 Further	 experiments	 showed	 not	 only	 membrane	 bound	 S.	 aureus	
lipoproteins	 are	 involved	 in	 binding	 to	 platelets	 (Figure	 3.5A)	 but	 S.	 aureus	
lipoproteins	 in	 the	 suspension	 can	 also	 bind	 platelets	 (Figure	 3.5B).	 These	
observations	suggest	that	S.	aureus	 lipoproteins	–	membrane	bound	or	 into	the	
extracellular	milieu,	can	bind	and	interact	with	platelets.	Percentage	aggregation	
was	 not	 affected	 in	 the	 absence	 of	 S.	 aureus	 lipoproteins	 (Figure	 3.1,	 3.2)	
suggesting	 that	 they	might	not	 influence	platelet	 function	when	present	on	 the	









ways.	 Some	 are	 involved	 in	 activation	 (Loughman	 et	 al.	 2005;	 Fitzgerald,	
Loughman,	et	al.	2006),	some	in	inhibition	(Waller	et	al.	2013)	and	some	only	in	
binding	(Sullam	et	al.	1996;	L.	O’Brien	et	al.	2002).	Assays	using	S.	aureus	lacking	





Ashraf,	 Byzova,	 Febbraio	 &	 E.	 a	 Podrez	 2008;	 Fälker	 et	 al.	 2014).	 Synthetic	
triacylated	lipoproteins	Pam3CSK4	are	know	to	activate	platelets	through	TLR2	
(Fälker	et	al.	2014;	Rivadeneyra	et	al.	2014;	Kälvegren	et	al.	2010),	but	the	effect	
of	 diacylated	 lipoproteins	 is	 as	 yet	 unknown.	 During	 their	 biogenesis	 in	 Gram	
negative	 bacteria,	 lipoproteins	 are	 triacylated	 by	 N-acyltransferase	 (Lnt)	
whereas	 Gram	 positive	 bacteria	 lack	 an	 Lnt	 homolog	 and	 produce	 diacylated	
lipoproteins	(Kovacs-Simon	et	al.	2011;	Nakayama	et	al.	2012).	S.	aureus,	a	Gram	








	 In	 order	 to	 evaluate	 their	 response	 to	 S.	 aureus	 lipoproteins,	 platelets	
were	preincubated	with	membrane	protein	extracted	from	S.	aureus	ΔltaS	and	S.	
aureus	ΔltaS	 lgt,	 then	 stimulated	with	 thrombin	 or	 CRP.	 Thrombin	 is	 a	 potent	
activator	of	platelet	activation	and	coagulation	(Kahn	et	al.	1998).	On	damage	to	
the	vessel	wall,	tissue	factors	are	released	which	act	on	zymogen	prothrombin	to	
form	 thrombin	 (Kuharsky	 &	 Fogelson	 2001).	 With	 the	 exposed	 endothelial	
matrix	components	playing	role	in	adhesion	of	platelets	(Gardiner	et	al.	2010),	a	
minute	 amount	 of	 thrombin	 induces	 their	 activation.	 When	 activated,	 more	
platelets	 are	 recruited	 (Offermanns	 2006)	 and	more	 thrombin	 is	 formed	 thus	
amplifying	 the	 response	 (Sinha	 et	al.	 1983;	Wolberg	&	 Campbell	 2008).	 Along	
with	activation	of	platelets,	thrombin	acts	on	fibrinogen	to	form	fibrin	(Kumar	et	
al.	1994)	which	forms	mesh	like	structures	with	platelets,	leading	to	a	stable	clot	
(Weisel	 2007).	 Thrombin	 is	 a	 protease	 and	 activates	 platelets	 via	 Protease	
activated	receptors	(PAR’s),	G-protein	coupled	receptors	(Kahn	et	al.	1998;	Chen	
et	 al.	 2013).	 PAR-1	 and	 PAR-4	 are	 known	 to	 be	 responsible	 for	 activation	 of	
human	platelets	upon	cleavage	by	thrombin	(Kahn	et	al.	1998).	PAR-1	can	cause	
activation	of	platelets	at	low	concentrations	of	thrombin	whereas	activation	via	
PAR-4,	 requires	 a	 high	 concentration	 of	 the	 protease	 (Kahn	 et	 al.	 1999).	 An	
activated	 PAR	 leads	 to	 activation	 of	 Gq	 (McCoy	 et	 al.	 2012),	 G12	 (Soto	 et	 al.	
2015),	 and	 Gi	family	 members	 (Woulfe	 et	 al.	 2002),	 which	 in	 turn	 cause	
activation	 of	 PLCβ,	 PI	 3-kinase,	 and	 the	 monomeric	 G	 proteins,	 Rho,	 Rac,	 and	




collagen	 receptor	 GPVI	 (Jung	 et	 al.	 2012).	 On	 damage	 to	 the	 vessel	 wall,	
endothelial	 matrix	 proteins	 are	 exposed	 to	 the	 blood	 stream	 (Hoylaerts	 et	 al.	
1997;	 Baruch	 et	 al.	 1991).	 One	 of	 the	major	 proteins	 present	 in	 the	matrix	 is	
collagen	 (Hoylaerts	et	al.	 1997),	which	 is	 composed	of	 repeating	GPO	 (Glycine,	
Proline	and	Hydroxyproline)	triplets	spread	out	throughout	the	molecule.	These	
GPO	triplets	are	arranged	in	triple	helical	structure	of	collagen	in	such	a	manner	
that	 are	 recognized	 by	 GPVI	 (Smethurst	 et	 al.	 2007).	 CRP-XL	 consist	 of	 10	
repeats	of	GPO	 triplets	 and	 is	made	of	 three	pepide	 chains	which	 cross-link	 to	
form	 collagen	 like	 structure	 that	 interacts	 with	 GPVI,	 leading	 to	 its	 activation	
(Smethurst	et	al.	2007).		
In	 the	 following	 chapter,	 the	 effect	 of	 S.	 aureus	 lipoproteins	 on	 platelet	
aggregation,	 αIIbβ3	 activation,	 granule	 release	 and	 spreading	 on	 fibrinogen,	
caused	after	stimulation	with	thrombin	and	CRP-XL	was	examined.	The	effect	on	
thrombus	 formation	 under	 flow	 on	 a	 collagen	 surface	 was	 checked	 by	 pre-










	 To	 check	 the	 effect	 of	 S.	 aureus	 lipoproteins	 on	 platelet	 aggregation,	
platelets	were	incubated	with	membrane	proteins	extracted	from	S.	aureus	ΔltaS	
and	S.	aureus	ΔltaS	lgt.	S.	aureus	lipoteichoic	acid	(LTA)	is	an	potent	inhibitor	of	
platelet	 activation	 (Waller	 et	 al.	 2013),	 so	 to	 avoid	 LTA	 contamination	 the	 S.	
aureus	 ΔltaS	 strain	 was	 used.	 Membrane	 proteins	 from	 S.	 aureus	 ΔltaS	 and	 S.	
aureus	 ΔltaS	 lgt	 did	 not	 cause	 platelet	 aggregation	 on	 their	 own.	 But	 pre-
incubation	 with	 membrane	 proteins	 from	 S.	 aureus	 ΔltaS	 inhibited	 the	
aggregation	 caused	 by	 CRP-XL	 (Figure	 4.1A),	 thrombin	 (Figure	 4.1B)	 and	 S.	
aureus	SH1000	(Figure	4.1C)	 in	a	dose	dependent	manner,	whereas	membrane	
proteins	extracted	from	S.	aureus	ΔltaS	lgt	had	no	effect.		
	 On	 increasing	 the	 concentration	 of	 CRP-XL,	 inhibition	 of	 platelet	
aggregation	 by	 membrane	 proteins	 from	 S.	 aureus	 ΔltaS	 was	 nullified	 (Figure	
4.1A).	Also	the	S.	aureus	ΔltaS	membrane	proteins	inhibited	platelet	aggregation	











Figure	 4.1:	 S.	 aureus	 lipoproteins	 inhibit	 platelet	 aggregation.	 A,B,C:	
Representative	 aggregation	 traces	 for	 platelets	 preincubated	 with	 membrane	
proteins	 from	 S.	 aureus	 and	 stimulated	 with	 CRP-XL	 (Ai),	 thrombin	 (Bi)	 and	 S.	
aureus	 SH1000	 (Ci).	 Aii,Bii,Cii: Data	 plotted	 as	 percent	 inhibition	 (platelets	


































































































































	 On	 activation,	 platelets	 undergo	 shape	 change	 and	 spread	 (Kita	 et	 al.	
2011).	 Platelet	 spreading	 is	 essential	 in	 coagulation	 and	 haemostasis.	 On	
spreading,	 a	 platelet	 flattens,	 increasing	 the	 surface	 area	 it	 covers,	 thus	
increasing	the	volume	of	the	clot	and	sealing	the	damaged	blood	vessel	(Lee	et	al.	
2012).	 Initial	 adhesion	 of	 platelets	 to	 the	 exposed	 component	 of	 damaged	
endothelium	 causes	 intracellular	 events	 leading	 to	 integrin	 activation	
(Nieswandt	et	al.	2009).	When	activated,	 integrin	αIIbβ3	can	bind	to	fibrinogen	
(Payrastre	et	al.	2000).	This	interaction	causes	outside	in	signalling	and	a	rise	in	
intracellular	 Ca2+	 that	 activates	 kinases	 responsible	 for	 platelet	 cytoskeleton	
rearrangement	 leading	to	platelet	spreading	(Lee	et	al.	2012).	 In	this	assay,	 the	
ability	 of	 platelets	 incubated	 with	 S.	 aureus	 lipoproteins	 to	 spread	 on	
immobilized	fibrinogen	was	tested.			



























different	 concentration	 of	 S.	 aureus	 membrane	 proteins.	 Control	 represents	
untreated	 platelets	 allowed	 to	 spread	 on	 fibrinogen.	 Platelets	with	 labelled	with	
philloidin	 647.	 B.	 Data	 plotted	 as	 percentage	 of	 platelets	 spread,	 non-spread,	
platelets	 with	 filopodia	 and	 platelets	 with	 lamilopodia	 after	 allowing	 platelets	



















































































4.2.3.	 S.	 aureus	 lipoproteins	 inhibit	 P-selectin	 exposure,	 PAC-1	 and	
fibrinogen	binding.	
Upon	activation	platelets	undergo	changes	such	as	activation	of	 integrin	
receptors	 (Nieswandt	et	al.	 2009)	and	release	of	granules	 (Flaumenhaft	2003).	
The	 major	 integrin	 αIIbβ3	 (Mehrbod	 et	 al.	 2013)	 undergoes	 conformational	
changes	and	converts	into	an	activated	form	(Payrastre	et	al.	2000)	which	can	be	
recognised	 by	 a	 PAC-1	 monoclonal	 antibody	 (Taub	 et	 al.	 1989).	 Binding	 to	
coagulation	 factors	 and	 plasma	 proteins	 is	 one	 of	 the	 essential	 functions	 of	
activated	integrin	αIIbβ3	to	facilitate	platelet-platelet	interaction	and	stable	clot	
formation	 (Mehrbod	et	al.	 2013).	One	 of	 the	major	 plasma	proteins	 capable	 of	
binding	 activated	 αIIbβ3	 is	 fibrinogen	 (Litvinov	 et	 al.	 2005).	 Another	
phenomenon	 important	 in	 platelet	 activation	 is	 the	 release	 of	 granules	
(Flaumenhaft	 2003).	 	 α	 –	 granules	 are	 the	 major	 granules	 in	 platelets	 that	






The	 effect	 of	 S.	 aureus	 lipoproteins	 on	 integrin	 αIIbβ3	 activation,	
fibrinogen	binding	and	P-selectin	exposure	caused	by	thrombin	(Figure	4.3)	and	
CRP-XL	 (Figure	 4.4)	 was	 measured	 by	 flow-cytometry.	 Pre-incubation	 of	
platelets	 with	 S.	 aureus	 ΔltaS	membrane	 proteins,	 inhibited	 activation	 of	 the	
integrin	 and	 binding	 of	 fibrinogen	 in	 a	 dose	 dependent	 manner.	 P-selectin	
exposure,	 and	 therefore	 platelet	 granule	 release,	 was	 also	 inhibited	 on	
	 101	





a	 major	 step	 leading	 to	 platelet	 shape	 change	 (Paul	 et	 al.	 1999)	 and	 various	
signalling	 events	 (Varga-Szabo	 et	 al.	 2009).	 Stimulus	 of	 platelets	 leads	 to	
activation	of	PLC	isoforms	(Nonne	et	al.	2005;	Lian	et	al.	2005;	Banno	et	al.	1998)	
which	 hydrolyses	 phosphoinositide	 4-5	 bisphosphate	 to	 form	 inositile	 1-4-5	
triphosphate	 (IP3)	 and	 diacyl	 glycerol	 (DAG)	 (Baldassare	 et	 al.	 1989).	 IP3	
induces	 release	 of	 calcium	 from	 intracellular	 compartments	 (Baldassare	 et	 al.	
1989;	 Varga-Szabo	 et	 al.	 2009)	 and	 DAG	 is	 involved	 in	 its	 entry	 from	
extracellular	 space	 by	 activating	protein	 kinases	 that	 activate	 the	 ion	 channels	
(Varga-Szabo	et	al.	2008).			
	 The	effect	of	S.	aureus	lipoproteins	on	the	increased	intracellular	calcium	
levels	 was	 measured	 by	 pre-incubating	 platelet	 rich	 plasma	 with	 membrane	
proteins	 extracted	 S.	 aureus	 ΔltaS	 and	 S.	 aureus	 ΔltaS	 lgt.	 Membrane	 proteins	
from	 S.	 aureus	 ΔltaS	 inhibited	 release	 of	 calcium	 in	 concentration	 dependent	
manner	(Figure	4.5	A,	B).	The	highest	concentration	(8	μg/ml)	of	S.	aureus	ΔltaS	
lgt	 membrane	 proteins	 did	 not	 inhibit	 calcium	 release	 (Figure	 4.5	 A,	 B)	




























Figure	 4.3:	S.	 aureus	 lipoproteins	 inhibit	 P-	 selectin	 expression,	 PAC1	 and	
fibrinogen	 binding	 of	 platelets	 stimulated	 with	 thrombin	 (0.05	 unit).	 (A)	
Histograms	representing	a	typical	experiment	out	of	three	performed	with	similar	
results,	 showing	 inhibition	 of	 PAC1binding,	 fibrinogen	 binding	 and	 P-Selectin	
exposure	 caused	 by	 thrombin	 on	 preincubation	 of	 platelets	 with	 S.	 aureus	
lipoproteins	 extract	 in	 a	 dose	 dependent.	 Grey	 histogram	 shows	 the	 control	 non-
stimulated	platelets.	 Preincubation	of	membrane	proteins	 extract	 from	S.	 aureus	
lgt	 LTA	 shows	no	change	 in	 fluorescence	 shift	 caused	by	PAC1binding,	 fibrinogen	













































































































Figure	 4.4:	 S.	 aureus	 lipoproteins	 inhibit	 P-	 selectin	 expression,	 PAC1	 and	
fibrinogen	 binding	 to	 platelets	 stimulated	 with	 CRP-XL.	 (A)	 Histograms	
representing	 a	 typical	 experiment	 out	 of	 three	 performed	 with	 similar	 results,	
showing	 inhibition	 of	 PAC1binding,	 fibrinogen	 binding	 and	 P-Selectin	 exposure	
caused	by	CRP-XL	on	preincubation	of	platelets	with	S.	aureus	lipoproteins	extract	
in	 a	 dose	 dependent.	 Grey	 histogram	 shows	 the	 control	 non-stimulated	 platelets.	
Preincubation	 of	 membrane	 proteins	 extract	 from	 S.	 aureus	 lgt	 LTA	 shows	 no	
change	 in	 fluorescence	 shift	 caused	 by	 PAC1binding,	 fibrinogen	 binding	 and	 P-

































































































Figure	 4.5:	 S.	 aureus	 lipoproteins	 inhibit	 intracellular	 calcium	 release	 in	
platelets	 stimulated	 with	 thrombin.	 PRP	 incubated	 with	 fura	 -2	 was	 treated	
with	 membrane	 proteins	 from	 S.	 aureus	 ΔltaS	 lgt	 at	 highest	 concentration	 and	
different	concentration	of	S.	aureus	ΔltaS,	then	stimulated	with	0.1	unit	thrombin.	
Control	 represents	 untreated	 platelets	 stimulated	 with	 thrombin	 (0.1	 unit)	 	 (A)	
Light	emission	at	340	and	380	nm	was	measured	and	340/380	ratios	were	plotted	




























































































	 In-vivo	 thrombus	 formation	 is	 initiated	 under	 constant	 flow	 and	 shear	
exerted	 by	 the	 vessel	wall	 (Badimon	 et	al.	 1989;	 Reininger	 2009).	 In	 order	 to	
depict	these	in-vivo	conditions	a	flow-based	assay	was	used	in	which	a	collagen-
coated	surface	acts	as	the	trigger	for	thrombus	formation.	Once	blood	flows	over	
the	 collagen,	 initial	 tethering	 of	 platelets	 to	 collagen	 fibers	 occurs	 via	 vWf	
through	platelet	glycoproteins	GPIb-V-IX	and	αIIbβ3	(Canobbio	et	al.	2004).	Due	
to	 this	 initial	 tethering,	 the	 flow	 of	 platelets	 is	 restricted	 allowing	 collagen	
receptors	GPVI	and	α2β1	on	platelets	to	bind	collagen	(Varga-Szabo	et	al.	2008).	
These	 interactions	 lead	 to	 intracellular	 signalling	 events	 which	 cause	 platelet	
activation	 and	 thus	 granule	 secretions	 that	 recruits	 more	 platelets	 to	 the	 site	
(Offermanns	 2006).	 In	 combination	 with	 plasma	 proteins	 and	 clotting	 factors,	
activated	platelets	lead	to	formation	of	a	stable	thrombus.			
	 On	incubation	of	blood	with	membrane	proteins	extracted	from	S.	aureus	
ΔltaS	 and	 S.	 aureus	ΔltaS	 lgt,	 extracts	 from	 S.	 aureus	ΔltaS	 inhibited	 thrombus	
formation	under	flow	(Figure	4.6).	Extracts	from	S.	aureus	ΔltaS	lgt	had	no	effect	
on	thrombus	formation	compared	to	control	suggesting	that	the	effect	was	due	
to	 S.	 aureus	 lipoproteins.	 The	 presence	 of	 S.	 aureus	 lipoproteins	 did	 not	 affect	











































Figure	4.6:	S.	 aureus	 lipoproteins	 inhibit	 thrombus	
formation	 under	 flow	 on	 collagen-coated	 surface.	
Whole	blood	was	treated	with	membrane	proteins	from	
S.	 aureus	 ΔltaS	 lgt	 and	S.	 aureus	 ΔltaS	 for	15	min.	On	
treatment,	platelets	were	stained	with	DIOC6	dye	 for	5	
min	 and	 then	 flowed	 over	 the	 collagen-coated	 (400	
μg/mL)	 Vena8TMBiochip	 (Cellex,	 Dublin)	 at	 a	 shear	
rate	 of	 20	 dynes/cm2.	 Z-stack	 images	 of	 forming	
thrombi	(A,	B,	C)	were	taken	every	30	sec	using	a	Nikon	
eclipse	 (TE2000-U)	 microscope.	 Volume	 of	 thrombus	





























































































































4.2.6.	 Synthetic	 diacylated	 lipoprotein	 MALP-2	 inhibits	 platelet	
aggregation.	
Earlier	 studies	 have	 reported	 that	 S.	 aureus	 lipoproteins	 are	 present	 in	
both	 diacylated	 (Tawaratsumida	 et	 al.	 2009)	 and	 triacylated	 (Asanuma	 et	 al.	
2011)	form.	But	Gram-positive	cocci	lack	the	lnt	gene	responsible	for	triacylation	
of	lipoproteins	(Hutchings	et	al.	2009),	thus	it	can	be	speculated	that	a	mixture	of	
S.	aureus	membrane	protein	 consists	predominantly	diacylated	 lipoproteins.	 In	
order	 to	 see	 whether	 this	 diacylated	 nature	 of	 lipoproteins	 has	 an	 effect	 on	
platelets,	a	diacylated	lipoproteins	MALP2	was	used.	MALP2	is	a	known	TLR2/6	
agonist,	and	platelets	express	both	TLR-2	and	6	(Buwitt-Beckmann	et	al.	2005).		
MALP2	 is	 a	 2	 kDa	 diacylated	 lipopeptide	 from	Mycoplasma	 fermentans	
(Borsutzky	 et	 al.	 2005).	 It	 is	 known	 to	 activate	 macrophages	 via	 TLR2/6	 and	
cause	 release	 of	 cytokines	 and	 chemokines	 (Galanos	 et	 al.	 2000).	 	 It	 also	




(Niebuhr	 et	 al.	 2008).	 In	 order	 to	 test	 the	 effect	 of	 MALP2	 platelets	 were	









Figure	 4.7:	 MALP-2	 inhibits	 platelet	 aggregation.	 A,B:	 Representative	
aggregation	 traces	 for	 platelets	 preincubated	 with	MALP-2	 and	 stimulated	 with	




























































































The	 effect	 of	 MALP-2	 on	 integrin	 αIIbβ3	 activation,	 fibrinogen	 binding	
and	P-selectin	exposure	caused	by	CRP-XL	(Figure	4.10)	was	analysed	by	 flow-





Mice	 are	 the	 preferred	model	 for	 haemostasis	 and	 thrombosis	 research	
(Nieswandt	 et	 al.	 2005)	 as	 well	 as	 for	 infections	 and	 pathogenesis	 caused	 by	





In	 order	 to	 see	whether	 S.	 aureus	 lipoproteins	 have	 the	 same	 effect	 on	
mouse	platelets	as	on	human,	mouse	platelet	 integrin	αIIbβ3	activation,	and	P-
selectin	exposure	caused	by	thrombin	(Figure	4.9	A)	and	CRP-XL	(Figure	4.9	B)	
was	 analysed	 by	 flow-cytometry.	 Pre-incubation	 of	 mouse	 platelets	 with	 S.	







Figure	 4.8:	 MALP-2	 inhibits	 P-	 selectin	 expression,	 PAC1	 and	 fibrinogen	
binding	 to	 platelets	 stimulated	 with	 CRP-XL.	 Platelets	 were	 incubated	 with	
different	 concentration	 of	 MALP-2	 and	 then	 stimulated	 with	 0.1	 μg/ml	 CRP-XL.	
Using	 flow	 cytometry	 activation	 of	 integrin	 αIIbβ3	 was	 measured	 by	 analysing	
binding	 of	 PAC-1	 and	 anti-fibrinogen	 antibodies	 whereas	 granule	 secretion	 was	
measured	 by	 assessing	 P-	 Selectin	 expression	 using	 anti	 CD62P	 antibody.	 A.	
Histograms	representing	a	typical	experiment	out	of	three	performed	with	similar	
results,	 showing	 inhibition	 of	 PAC1binding,	 fibrinogen	 binding	 and	 P-Selectin	
exposure	 caused	 by	 CRP-XL	 on	 preincubation	 of	 platelets	 with	 S.	 aureus	












































































































flow	 cytometry	 activation	 of	 mouse	 platelet	 integrin	 αIIbβ3	 was	 measured	 by	
analysing	 binding	 of	 JonA	 and	 granule	 secretion	 was	 measured	 by	 assessing	 P-	







































































	 Activation	 of	 platelets	 leads	 to	 direct	 platelet	 –	 platelet	 interaction	 and	
indirect	 binding	 through	 plasma	 proteins,	 causing	 formation	 of	 aggregates	
(Savage	 et	 al.	 1996;	 Kulkarni	 et	 al.	 2000).	 Activated	 integrin	 αIIbβ3	 plays	
essential	 role	 in	 binding	 to	 plasma	 proteins	 (Mehrbod	 et	 al.	 2013).	 	 S.	 aureus	
lipoproteins	 inhibit	 PAC1	 binding	 (Figure	 4.3B,	 4.4B)	 suggesting	 inhibition	 of	
integrin	 αIIbβ3	 activation.	 	 On	 stimulus	 of	 platelets	 by	 an	 agonist,	 initial	
signalling	 occurs	 causing	 an	 increase	 in	 intracellular	 calcium	 and	 inside-out	
signalling,	 leading	 to	 conformational	 change	 and	 activation	 of	 integrin	 αIIbβ3	
(Mehrbod	et	al.	2013).	The	initial	increase	in	calcium	occurs	in	the	presence	of	S.	
aureus	lipoproteins,	but	a	later	sustained	increase	in	calcium	is	inhibited	(Figure	





granules,	 α-granules	 are	 most	 prominent	 and	 P-selectin	 expression	 on	 the	
platelet	 surface	 is	 the	marker	 for	 their	 release	 (McGrath	et	al.	 2010).	S.	aureus	
lipoproteins	 inhibit	 expression	 of	 P-selectin	 (Figure	 4.3C,	 4.4C)	 thus	 inhibit	
granule	release.	Binding	of	fibrinogen	is	essential	for	the	platelet	clot	formation	
(Kumar	 et	 al.	 1994).	 The	main	 receptor	 for	 fibrinogen	 on	 platelets	 is	 integrin	
αIIbβ3	(Mehrbod	et	al.	2013).	Binding	of	fibrinogen	to	integrin	αIIbβ3	induces	its	
clustering	 which	 causes	 outside	 in	 signalling	 leading	 to	 complete	 platelet	
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activation	 (Gaul	 et	 al.	 2015).	 S.	 aureus	 lipoproteins	 inhibit	 fibrinogen	 binding	
(Figure	4.3D,	4.4D)	thus	inhibit	integrin	αIIbβ3	activation	and	clustering.		
	 The	 interaction	 of	 fibrinogen	 and	 clustering	 of	αIIbβ3	 causes	 outside	 in	
signalling	 leading	 to	 platelets	 spreading	 (Zhi	 et	 al.	 2015a).	 Different	 stages	 in	
platelet	 spreading	 are	 the	 result	 of	 different	 signalling	 events	 that	 occur	 once	
integrin	 αIIbβ3	 is	 activated	 (Lee	 et	 al.	 2012).	 In	 the	 presence	 of	 S.	 aureus	
lipoproteins,	 spreading	 is	 completely	 inhibited.	 Even	 in	 the	 presence	 of	 sub-
inhibitory	 concentrations,	 platelets	 either	 exist	 as	 completely	 spread	 or	 non-
spread.	 This	 suggests	 that	 on	 exposure	 of	 a	 platelet	 to	 S.	 aureus	 lipoproteins,	
outside	 in	 signalling	 is	 completely	 blocked.	 Increased	 exposure	 to	 fibrinogen	
over	 time	 does	 not	 affect	 the	 inhibition	 of	 platelet	 spreading	 by	 S.	 aureus	
lipoproteins	 (Figure	 4.5).	 This	 observation	 points	 out	 that	 once	 platelets	 are	
exposed	 to	 S.	 aureus	 lipoproteins,	 they	 inhibit	 integrin	 αIIbβ3	 activation	 and	
clustering,	thus	completely	inhibiting	outside	in	signalling.		
	 The	 thrombus	 formation	under	 flow	assay	 is	a	close	depiction	of	 the	 in-










	 Synthetic	 diacylated	 lipoprotein	 MALP-2	 inhibits	 platelet	 aggregation,	
activation	 of	 integrin	 αIIbβ3,	 binding	 of	 fibrinogen	 and	 platelet	 granule	
secretion.	 On	 other	 cells	 like	 macrophages,	 MALP-2	 shows	 its	 activity	 at	 low	
concentration	 (Deiters	 &	 Mühlradt	 1999)	 than	 that	 used	 in	 current	 study	 to	
cause	 the	 effect	 on	 platelets.	 This	 suggests	 that	 MALP-2	 as	 like	 S.	 aureus	
lipoproteins	is	also	be	a	weak	inhibitor	of	platelet	activation	(Figure	4.7,	4.8).			
	 Mouse	 platelet	 activation	 was	 not	 inhibited	 by	 S.	 aureus	 lipoproteins.	
Even	 though	mice	 are	 considered	 as	 the	 closest	model	 to	 humans	 for	 platelet	
studies,	 there	are	 significant	 structural	 and	morphological	differences	between	
human	and	mouse	platelets	 (Schmitt	et	al.	2001).	Mouse	platelets	compared	 to	
human	platelets	are	smaller	in	size,	differ	in	granule	content	(Schmitt	et	al.	2001)	
and	 have	 differences	 in	 some	 surface	 receptors	 like	 PAR’s	 (Sambrano	 et	 al.	
2001).	Mouse	platelets	also	lack	FcΥRIIA,	an	receptor	for	IgG	present	on	human	
platelets	 (Jirouskova	 et	 al.	 2007).	 	 Studies	 have	 reported	 that	mouse	 platelets	
respond	 differently	 compared	 to	 human	 platelets	 for	 some	molecules	 binding	
and	affecting	αIIbβ3	(Basani	et	al.	2008).	The	structural	difference	in	mouse	and	
human	platelets	might	be	 the	reason	 that	mouse	platelets	do	not	 respond	 to	S.	
aureus	lipoproteins	as	human	platelets	(Figure	4.9).	
	 Overall	 S.	 aureus	 lipoproteins	 are	weak	 inhibitors	 of	 platelet	 activation.	
Initial	 binding	 of	 platelets	 to	 plasma	 proteins	 (collagen	 and	 fibrinogen)	 is	 not	
affected	in	the	presence	of	S.	aureus	lipoproteins	but	later	platelet	activation	and	
thrombus	 formation	 is	 inhibited.	 Flow	 cytometry	 and	 spreading	 data	 strongly	




platelets	 for	 clot	 formation	 is	 also	 inhibited	 in	 the	 presence	 of	 S.	 aureus	





























	 S.	 aureus	 lipoproteins	 are	 one	 of	 the	major	molecule	 recognised	 by	 the	
host	 immune	system	(Li	et	al.	2008)	and	a	 lack	of	 lipoproteins	on	the	S.	aureus	
surface	 reduces	 the	 ability	 of	 the	 immune	 system	 to	 clear	 S.	 aureus	 infection	
(Bubeck	Wardenburg	et	al.	 2006).	S.	aureus	 lipoproteins	 are	known	 to	 interact	
with	TLR2	(Li	et	al.	2008).	Localization	of	S.	aureus	lipoproteins	on	TRL2	induces	
signalling	via	MyD88	 in	murine	macrophages	 (Schmaler	et	al.	 2009)	 leading	 to	
nitric	oxide	synthesis	(Kim	et	al.	2015),	interleukin	production	(Kang	et	al.	2015;	
Müller	 et	 al.	 2010)	 and	 an	 inflammatory	 response	 (Schmaler	 et	 al.	 2009).	 In	
human	 corneal	 epithelial	 cells,	 S.	 aureus	 lipoproteins	 cause	 an	 innate	 immune	
response	on	binding	to	TRL2	via	NF-κB,	JNK,	and	p38	signalling	(Li	et	al.	2008).	S.	
aureus	lipoproteins	also	cause	activation	of	caspase	1	and	induce	IL-1β	secretion,	
promoting	 haemolysis	 (Kim	 et	 al.	 2011).	 Overall,	 S.	 aureus	 lipoproteins	 are	
capable	 of	 binding	 to	 host	 cells,	 where	 they	 induce	 signalling,	 causing	 a	
physiological	response.	
	 Platelet	 function	 is	 affected	 on	 interaction	 with	 lipoproteins	 (Rex	 et	 al.	
2009;	 Ghosh	 et	 al.	 2011).	 Synthetic	 triacylated	 lipoprotein	 Pam3CSK4	 causes	
platelet	 activation	 via	 TRL2	 (Rex	 et	 al.	 2009;	 Rivadeneyra	 et	 al.	 2014).	
Stimulation	of	platelets	by	Pam3CSK4	causes	P2X1-dependent	Ca2+	mobilisation	
(Kälvegren	 et	 al.	 2010),	 activation	 of	 src/Syk/LAT/PLCγ2	 signalling	 cascade	
(Fälker	 et	 al.	 2014)	 and	 NF-κB	 activation	 (Rivadeneyra	 et	 al.	 2014).	 Plasma	
oxidised	low-density	lipoproteins	cause	platelet	activation	via	CD36	(Ghosh	et	al.	
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2011;	 Nergiz-Unal	 et	al.	 2011).	 Interaction	 between	 platelet	 CD36	 and	 plasma	
oxidised	 low-density	 lipoproteins	 causes	 activation	 of	 protein	 tyrosine	 kinase	
Syk	 (Nergiz-Unal	 et	 al.	 2011)	 and	 CD36/NOX2	 mediated	 inhibition	 of	 the	
cGMP/protein	 kinase	 G	 signalling	 cascade	 in	 platelets	 (Magwenzi	 et	 al.	 2015).	
Whereas	plasma	oxidised	high-density	lipoproteins	interact	with	SRB1	leading	to	
inhibition	of	platelet	activation	and	aggregation	(Valiyaveettil	et	al.	2008).		
	 Lipoproteins	 play	 a	 significant	 part	 in	 recognition	 of	 S.	 aureus	 by	 the	
immune	system	(Stoll	et	al.	2005)	and	platelets	express	the	surface	receptors	for	
other	 types	 of	 lipoprotein	 which,	 on	 interaction	 also	 affect	 platelet	 function	
(Magwenzi	 et	 al.	 2015;	 Valiyaveettil	 et	 al.	 2008).	 In	 the	 following	 chapter,	 a	






	 In	order	 to	 identify	platelet	 receptors	of	S.	aureus	 lipoproteins,	 proteins	
from	 platelet	 lysates	 were	 co-precipitated	 with	 biotin	 tagged	 S.	 aureus	
lipoproteins	and	visualized	by	silver	stained	SDS	PAGE	gels.	A	numbers	of	bands	
were	 visible	 compared	 to	 control	 that	 represented	 entire	 set	 of	 proteins	 from	
platelet	proteome	co-precipitating	with	S.	aureus	lipoproteins	(Figure	5.1).	Eight	
different	 bands	 not	 present	 in	 the	 control	were	 chosen	 for	mass	 spectrometry	
analysis.	Mass	spectrometry	analysis	provided	the	score	and	coverage	values	for	
the	 proteins	 identified.	 The	 coverage	 value	 is	 the	 percentage	 of	 the	 protein	
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sequence	covered	by	 the	 identified	peptides.	The	score	value	 is	 the	estimate	of	





the	 80	 to	 90	 kDa	 range	 (band	 3	 –	 Figure	 5.2),	 which	 was	 in	 the	 expected	
molecular	weight	range	(88	kDa)	as	reported	for	it	(Park	2014).	
	 Other	 platelet	 surface	 proteins	 found	 in	 the	 entire	 mass	 spectrometry	
prediction	were	CD109	antigen,	GPV,	GPVI,	GPIbα,	GPIbβ	and	integrin	β3.		CD109	
is	 considered	 clinically	 significant	 due	 to	 the	 presence	 of	 antibodies	 against	 it,	
which	 are	 associated	 with	 complications	 such	 as	 thrombocytopenia	 and	 post-
transfusion	purpura	(Hwang	et	al.	2013;	Ertel	et	al.	2005).	Co	–	precipitation	of	
integrin	 receptors	 may	 be	 significant	 in	 the	 functional	 effect	 of	 S.	 aureus	
lipoproteins	on	platelets.	However	 the	 low	 score	 and	 coverage	 suggests	 that	 it	













																			 						 				 	 	
	
Figure	 5.1:	 Platelet	 proteins	 co-precipitated	 with	 S.	 aureus	 lipoproteins.	
Platelet	lysates	treated	with	biotinylated	S.	aureus	lipoproteins.	Co-precipitated	of	
S.	aureus	lipoproteins	was	done	using	streptavidin	beads.	Silver	stained	SDS	PAGE	






















































































































































































Figure	 5.2:	 Mass	 Spectrometry	 analysis	 for	 Platelet	 surface	 proteins	 co-
precipitated	with	S.	aureus	lipoproteins.	A.	Mass	Spectormetry	prediction	score	
and	 protein	 coverage	 only	 for	 platelet	 surface	 proteins	 obtained	 from	 numerous	
proteins	 co-precipitated	 with	 S.	 aureus	 lipoproteins.	 CD36	 showed	 highest	 score	
and	 coverage.	 B.	 Silver	 stained	 SDS	 PAGE	 gel	 showing	 platelet	 proteins	 co-




























S.	aureus	 lipoproteins	 bind	 CD36,	 a	 co-	 immunoprecipitation	 assay	were	 done.	
Co-immuno	 precipitations	 for	 CD36	 on	 platelets	 treated	 with	 biotinylated	 S.	
aureus	lipoproteins	showed	that	S.	aureus	lipoproteins	bound	CD36	(Figure	5.3).	
Negative	 controls	with	 only	magnetic	 beads,	 anti-CD36	 antibody	 and	 S.	aureus	
lipoproteins	 (Figure	5.3	–	band	1	 in	 the	western	blot)	did	not	 show	any	bands	
which	 rules	 out	 any	 non-specific	 binding	 and	 suggests	 that	 the	 S.	 aureus	










Platelet	 lysate	 treated	 with	 biotinylated	 S.	 aureus	 lipoproteins	 plus	 anti-CD36	
antibody	 and	 co-immunoprecipitated	 with	 protein	 A/G	 magnetic	 beads.	 Co-
immunoprecipitated	 proteins	were	 blotted	 and	 developed	with	 streptavidin	HRP.	
Western	blot	 showing	S.	 aureus	 lipoproteins	 co-precipitating	with	platelet	 CD36.	






























































































	 Synthetic	 lipoprotein	 Pam3CSK4	 interact	 with	 TLR2	 and	 cause	 platelet	
actvation	(Fälker	et	al.	2014),	whereas	high	density	oxidised	plasma	lipoproteins	
interact	with	 SRB1	 (Valiyaveettil	 et	al.	2008)	 and	 inhibit	 platelet	 function.	 But	
mass	spectrometry	data	from	co-precipitation	of	platelet	proteins	with	S.	aureus	
lipoproteins	did	not	show	the	presence	of	TLR2	or	SRB1	(Figure	5.2).	To	confirm	
that	TRL2	and	SRB1	are	not	 involved	 in	 inhibition	of	CRP-XL	mediated	platelet	
activation	caused	by	S.	aureus	lipoproteins,	neutralisation	assays	were	done.	Anti	
TLR2	 and	 anti	 SRB1	 antibodies	 did	 not	 significantly	 affect	 CRP-XL	 mediated	
platelet	aggregation.	After	treating	platelets	with	monoclonal	anti-TRL2	or	anti-








mediated	 via	 TRL2	 or	 SRB1.	 A.	 Data	 plotted	 as	 percentage	 of	 inhibition	 of	
platelet	 aggregation	 caused	 by	 S.	 aureus	 ΔltaS	 membrane	 proteins	 on	 pre-
incubating	platelets	with	anti	TLR2	or	anti	SRBI	and	then	stimulating	with	CRP-XL.	



































































	 Plasma	 oxidised	 LDL	 is	 known	 to	 cause	 platelet	 aggregation	 via	 CD36	
(Magwenzi	et	al.	2015).	On	neutralising	platelet	CD36	with	anti-CD36	antibody,	
platelet	 aggregation	 caused	 by	 plasma	 oxidised	 LDL	 (10	 μg/ml)	was	 inhibited	
(Figure	 5.5A).	 In	 the	 same	 way,	 incubating	 platelets	 with	 S.	 aureus	 ΔltaS	
membrane	 proteins,	 also	 inhibited	 platelet	 aggregation	 caused	 by	 plasma	
oxidised	LDL	in	a	dose	dependent	manner	(Figure	5.5B).	There	was	no	effect	of	
treatment	 with	 isotype	 control	 and	 S.	 aureus	 ΔltaS	 lgt	membrane	 proteins	 on	
platelet	aggregation	caused	plasma	oxidised	LDL	(Figure	5.5	A,	B).		
5.2.5:	 Neutralisation	 of	 platelet	 CD36	 abrogates	 inhibitory	 effect	 of	 S.	
aureus	lipoproteins	on	platelet	aggregation.	
	 On	establishing	that	CD36	is	a	platelet	receptor	for	S.	aureus	lipoproteins,	
the	 next	 step	 was	 to	 test	 whether	 CD36	 is	 responsible	 for	 the	 functional	
inhibition	 of	 platelet	 activation.	 On	 neutralising	 platelet	 CD36	 using	 anti-CD36	
antibody,	inhibition	of	platelet	aggregation	caused	by	S.	aureus	lipoproteins	was	
nullified	(Figure	5.6).	Platelets	aggregated	normally	in	the	presence	of	anti-CD36	








Figure	 5.5:	 S.	 aureus	 lipoproteins	 inhibit	 platelet	 aggregation	 caused	 by	
oxidized	 LDL.	 Ai,Bi.	 Data	 plotted	 as	 percent	 aggregation	 caused	 by	 plasma	
oxidised	LDL	(10	μg/ml)	on	pre-treatment	of	platelets	with	anti-CD36	(Ai)	and	S.	
aureus	membrane	proteins	(Bi).	Data	represent	mean	values	±	SEM.	(n=3,	*P<0.05	
































































































Figure	 5.6:	 Inhibition	 of	 platelet	 aggregation	 by	 S.	 aureus	 lipoproteins	 is	
inhibited	 on	 neutralisation	 of	 CD36.	 A.	Data	plotted	as	 percentage	 of	 platelet	































































5.2.6:	 Neutralisation	 of	 platelet	 CD36	 abrogates	 inhibitory	 effect	 of	 S.	
aureus	lipoproteins	on	platelet	spreading	on	fibrinogen.	
	 On	 neutralising	 platelet	 CD36	 with	 anti-CD36	 antibody,	 inhibition	 of	
spreading	 by	 S.	 aureus	 lipoproteins	 was	 nullified	 (Figure	 5.7	 A-B).	 Platelets	




5.2.7:	 Neutralisation	 of	 platelet	 CD36	 abrogates	 inhibitory	 effect	 of	 S.	
aureus	 lipoproteins	on	platelet	P-selectin	exposure,	PAC-1	and	 fibrinogen	
binding.	
	 S	 aureus	 lipoproteins	 inhibit	 activation	 of	 platelet	 integrin	 αIIbβ3	 and	
platelet	granule	release.	On	neutralising	platelet	CD36	with	anti-CD36	antibody	
it	 was	 seen	 that	 inhibition	 of	 PAC-1	 binding	 (Figure	 5.8A),	 fibrinogen	 binding	
(Figure	 5.8B)	 and	 P-	 selectin	 exposure	 (Figure	 5.8C)	 caused	 by	 S.	 aureus	
lipoproteins,	was	nullified.	There	was	no	effect	of	treatment	with	isotype	control	
antibody.	The	effect	of	anti-CD36	occurred	 in	a	dose	dependent	manner.	These	






















Figure	 5.7:	 Inhibition	 of	 platelet	 spreading	 on	 fibrinogen	 by	 S.	 aureus	
lipoproteins	 is	 inhibited	 by	 neutralisation	 of	 CD36.	 A.	 Images	 taken	 by	
fluorescence	 microscopy	 of	 platelet	 spreading	 on	 fibrinogen.	 Platelets	 were	
pretreated	with	different	concentration	of	anti-CD36	antibody,	then	with	S.	aureus	
ΔltaS	membrane	 proteins	 (8	 μg/ml)	 and	 allowed	 to	 spread	 on	 fibrinogen	 for	 45	
min.	 Control	 represents	 untreated	 platelets	 allowed	 to	 spread	 on	 fibrinogen.	
Platelets	 labelled	 with	 philloidin	 647.	 B.	 Data	 plotted	 as	 percentage	 of	 platelets	
spread,	 non-spread,	 platelets	 with	 filopodia	 and	 platelets	 with	 lamilopodia	 after	
allowing	 platelets	 incubated	 with	 different	 concentration	 of	 anti-CD36	 and	 S.	






































CRP-XL.	 Using	 flow	 cytometer	 activation	 of	 integrin	 αIIbβ3	 was	 measured	 by	
analysing	 binding	 of	 PAC-1	 and	 anti-fibrinogen	 antibodies	 whereas	 granule	
secretion	 was	 measured	 by	 looking	 at	 P-	 Selectin	 expression	 using	 anti	 CD62P	
antibody.	(A)	Histograms	representing	a	typical	experiment	out	of	three	performed	
with	similar	results,	showing	nullification	of	inhibition	of	PAC1binding,	fibrinogen	
binding	 and	 P-Selectin	 exposure	 caused	 by	 S.	 aureus	 lipoproteins	 extract	 on	
incubation	 with	 anti	 CD36	 antibody	 in	 a	 dose	 dependent.	 Data	 plotted	 as	
percentage	 of	 fluorescence	 intensity	 for	 binding	 of	 PAC-1	 antibody	 (A),	 anti	
fibrinogen	antibody	(B)	and	anti	CD62P	(C)	to	platelets.	Control	shows	the	data	for	





















































































	 Lipoproteins	 can	 modulate	 platelet	 function	 (Rex	 et	 al.	 2009).	 Known	
receptors	 for	 lipoproteins	 include	 toll	 like	 receptors	 (TLR’s)	 (Brightbill	 et	 al.	
1999)	and	scavenger	receptors	(Canton	et	al.	2013),	many	of	which	are	present	
on	 platelets	 (Silverstein	 &	 Febbraio	 2009;	 F	 Cognasse	 et	 al.	 2005).	 S.	 aureus	
lipoproteins	 are	 essential	 pattern	 recognition	 molecules	 on	 the	 S.	 aureus	 cell	
surface	 (Wardenburg	 et	 al.	 2006)	 and	 affect	 the	 function	 of	 immune	 cells	 via	
TLR2	 (Li	 et	 al.	 2008;	 Müller	 et	 al.	 2010).	 Platelets	 express	 TRL2,	 and	 the	
triacylated	lipoproteins	Pam3CSK4	alters	platelet	function	via	TLR2	(Fälker	et	al.	
2014),	 thus	 it	was	 hypothesised	 to	 be	 a	 platelet	 surface	 receptor	 for	S.	aureus	
lipoproteins.	 Similarly	 high-density	 lipoproteins	 inhibit	 platelet	 activation	 via	
scavenger	receptor	B1	(SRB1)	(Valiyaveettil	et	al.	2008).	Due	to	inhibitory	ability	
of	S.	aureus	 lipoproteins,	SRB1	was	considered	to	be	another	potential	receptor	
for	 these	 lipoproteins.	 But	 the	neutralisation	 of	 either	 receptor	 (Figure	5.4)	 as	
well	as	the	mass	spectrometry	data		(Figure	5.2)	did	not	support	a	role	for	either.		
On	mass	 spectrometry	 analysis	 of	 platelet	 proteins	 co-precipitated	with	
biotin	 tagged	 S.	 aureus	 ΔltaS	 membrane	 proteins,	 surface	 proteins	 co-
precipitated	included	CD36,	CD109,	GPV,	GPVI,	GPIbα	and	β3.	Among	all	of	them,	
CD36	had	the	highest	mass	spectrometry	prediction	score	and	coverage	(Figure	
5.2)	 suggesting	 that	 it	 was	 the	 surface	 protein	 that	 was	 more	 strongly	 co	
precipitated	with	S.	aureus	lipoproteins.	Co-immunoprecipitation	of	CD36	in	the	
presence	 of	 biotinylated	 S.	 aureus	 membrane	 proteins	 showed	 that	 in	
comparison	 to	 the	 control,	 nearly	 all	 S.	 aureus	 membrane	 proteins	 co-
precipitated	 with	 CD36	 (Figure	 5.3),	 thus	 confirming	 that	 it	 interacts	 with	 S.	
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aureus	 lipoproteins.	Functional	blocking	of	platelet	 surface	SRB1	and	TLR2	did	
not	 show	 any	 effect	 on	 S.	 aureus	 lipoproteins	 mediated	 inhibition	 of	 platelet	
activation	 thus	 co-precipitation	 assay	 was	 not	 performed,	 but	 there	 ability	 to	
interact	with	S.	aureus	lipoproteins	cannot	be	ruled	out.		
	 It	 is	 been	 reported	 that	 plasma	 oxidised	 low-density	 lipoproteins	 cause	
activation	of	platelets	via	CD36	(Magwenzi	et	al.	2015).	This	was	supported	by	
our	 analysis	 as	 well.	 After	 neutralising	 CD36	 on	 the	 platelet	 surface,	 platelet	
aggregation	 caused	 by	 plasma	 oxidised	 LDL	 was	 inhibited	 (Figure	 5.5A).	 Pre-
incubation	 of	 platelets	 with	 S.	 aureus	 ΔltaS	membrane	 proteins	 also	 inhibited	
platelet	 aggregation	 caused	 by	 plasma	 oxidised	 LDL	 (Figure	 5.5B).	 Thus	
suggesting	that	S.	aureus	 lipoproteins	might	bind	to	CD36	and	in	turn	block	the	
access	of	plasma	oxidised	LDL,	to	cause	any	effect	on	platelets.		
On	 neutralising	 CD36	 on	 the	 platelet	 surface,	 inhibition	 of	 platelet	
aggregation	 (Figure	 5.6),	 platelet	 spreading	 (Figure	 5.7),	 integrin	 αIIbβ3	
activation	(Figure	5.8A,B)	and	platelet	granule	release	(Figure	5.C)	caused	by	S.	
aureus	 lipoproteins,	was	abolished.	These	data	show	that	S.	aureus	 lipoproteins	












	 Platelet	CD36	 is	 involved	 in	 inhibition	of	platelet	activation	by	S.	aureus	
lipoproteins.	 This	 88kDa	 (Park	 2014)	 major	 glycoprotein	 on	 platelet	 surface	
(Cserti-Gazdewich	 et	 al.	 2009)	 is	 considered	 to	 be	 a	 receptor	 for	
thrombospondin	(Wu	1995)	and	collagen	(Nieswandt	&	Watson	2003).	Binding	
of	 oxidized	 low-density	 lipoprotein	 to	 CD36	 on	 the	 platelet	 surface	 leads	 to	
activation	 (Magwenzi	et	al.	 2015).	 CD36	 is	 also	 known	 to	be	 receptor	 for	 fatty	
acids	 (Pepino	 et	 al.	 2014),	 anionic	 phospholipids	 (Wagner	 1996),	 and	
plasmodium	 falciparum	malaria	 parasitized	 erythrocytes	 (Cserti-Gazdewich	 et	
al.	 2009).	 Along	 with	 platelets,	 it	 is	 present	 on	 immune	 (Podrez	 et	 al.	 2000),	
endothelial	and	epithelial	cells	(Park	2014).		
	 Structurally	 CD36	 has	 two	 trans	 membrane	 domains,	 both	 N-	 and	 C-	
terminals,	embedded	in	membrane	(Wagner	1996).	It	has	short	cytoplasmic	tails	
and	the	majority	of	the	protein	is	present	in	extracellular	space	(Wagner	1996).	
CD36	 is	 heavily	 glycosylated	 at	 its	 large	 extracellular	 region	 (Hoosdally	 et	 al.	
2009).	 There	 are	 ten	 known	 glycosylation	 sites	 present	 in	 this	 loop,	 of	 which	
nine	 are	 known	 to	 be	modified	 during	 trafficking	 of	 the	 protein	 to	 the	 plasma	
membrane	 (Hoosdally	 et	 al.	 2009).	 Defect	 in	 glycosylation	 block	 receptor	
trafficking,	but	glycosylation	is	not	seen	to	be	essential	for	ligand	(oxidised	LDL)	
recognition	 (Pepino	 et	al.	 2014).	 The	 extracellular	 domain	 of	 CD36	 consists	 of	
three	 disulphide	 bridges	 at	 the	 carboxyl-terminal	 side	 (Gruarin	 et	 al.	 1997).	
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Amino	acids	residues	87	 to	279	 form	a	 loop	and	are	speculated	 to	be	a	part	of	
binding	pocket	for	CD36	ligands	(Pepino	et	al.	2014)	(Figure	6.1).	
	 The	intracellular	portion	of	CD36	is	smaller	at	the	amino	terminal	but	it	is	
large	 enough	 at	 the	 carboxyl	 terminal	 end	 to	 allow	 binding	 and	 activation	 of	
protein	 kinases,	 leading	 to	 intracellular	 signalling	 (Silverstein	 et	 al.	 2010).	 In	
many	 instances,	 interaction	 of	 ligands	 with	 CD36	 causes	 activation	 of	 Src	
tyrosine	 kinases	 (Bull	 et	 al.	 1994).	 In	 Cho	 cells	 and	monocytes,	 stimulation	 of	
CD36	 causes	 increase	 in	 intracellular	Ca2+	 level	 (Kuda	et	al.	 2011).	 In	platelets	
stimulation	 of	 CD36	 by	 TSP-1	 or	 oxidised	 LDL	 causes	 a	 Src	 kinases	 mediated	
increase	 in	 intracellular	 Ca2+	 level	 (Nergiz-Unal	 et	 al.	 2011).	 Stimulation	 of	
platelets	 by	 oxidised	 LDL	 causes	 Src	 kinases	 and	 Protein	 kinase	 C	 dependent	
phosphorylation	and	activation	of	NOX2.	Activation	of	NOX2	increases	the	level	
of	 reactive	 oxygen	 intermediates	 (ROI)	 and	 dampening	 of	 cGMP	 mediated	
signalling	 (Magwenzi	 et	 al.	 2015).	 Binding	 of	 TSP-1	 also	 causes	 dampening	 of	
cGMP	 mediated	 signalling,	 thus	 promoting	 platelet	 activation	 (Isenberg	 et	 al.	




	 Binding	 of	 S.	 aureus	 lipoproteins	 to	 platelet	 CD36	 leads	 to	 inhibition	 of	
platelet	activation	by	known	physiological	agonists	 (CRP-XL	and	Thrombin).	 In	








showing	 sites	 for	 thrombospondin	 binding	 (amino	 acids	 87	 to	 91),	 collagen	 and	
oxidised	 LDL	binding	 (amino	acid	 155	 to	 183)	 and	 long	 chain	 fatty	 acid	 binding	
(amino	acid	204	to	234).	CD36	has	three	disulphide	bonds	at	carboxyl	side	and	six	
known	glycosylation	sites.	Towards	the	cytoplasmic	region	CD36	is	acylated	at	four	












	 Vasodilator-stimulated	 phosphoprotein	 (VASP)	 is	 associated	 with	 actin	
filaments	and	focal	adhesions	and	is	a	regulator	of	actin	dynamics	(Aszodi	et	al.	
1999).	VASP	is	regulated	by	cAMP	and	cGMP	dependent	protein	kinases	(Li	et	al.	
2003).	 Physiological	 platelet	 activation	 inhibitors	 like	 prostacyclin	 (PGI2)	 and	
nitric	oxide	(NO)	increases	the	levels	of	cAMP	and	cGMP	respectively	(Pohl	et	al.	
1994).	 	The	marker	 for	 increased	 levels	of	cAMP	is	phosphorylation	of	VASP	at	
Ser239	and	for	cGMP	is	phosphorylation	of	VASP	at	Ser157	(Defawe	et	al.	2010).	
Nitric	 oxide	 inhibits	 platelet	 function	 by	 binding	 to	 soluble	 guanylyl	
cyclase	 enzyme	 (sGC)	 that	 increases	 the	 levels	 of	 cGMP	 (Crane	 et	 al.	 2005).	
Increased	intracellular	levels	of	cGMP	affects	multiple	signalling	pathways,	such	
as	 cGMP-dependent	 receptor	 proteins,	 cGMP-regulated	 phosphodiesterases	
(PDE),	and	cGMP-dependent	protein	kinases	(Wang	et	al.	1998).	It	also	causes	a	
decrease	in	intracellular	calcium	levels	and	inhibits	integrin	αIIbβ3	activation	(Li	
et	al.	2006).	Upon	 increased	 in	 intracellular	cGMP	levels,	 the	binding	affinity	of	
αIIbβ3	 for	 fibrinogen	 is	 also	 decreased	 by	 cGMP-dependent	 inhibition	 of	
phosphoinositide	 3-kinase	 activation	 (PI3K)	 and	 by	 cGMP-dependent	
phosphorylation	of	the	vasodilator-stimulated	phosphoprotein	(VASP)	at	Ser157	
(Li	et	al.	2003).	  
Prostacyclin	 (PGI2)	 inhibits	platelet	 function	by	binding	 to	 its	G-protein	
coupled	 receptor	 on	 platelets	 (Klockenbusch	 et	 al.	 1996).	 On	 binding,	 PGI2	
causes	 a	 receptor	 induced	 signalling	 cascade,	 which	 induces	 adenylyl	 cyclase,	
leading	to	an	increase	in	cAMP	levels.		Increase	in	cAMP	level	causes	activation	of	
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PKA	 that	 causes	 phosphorylation	 of	 several	 proteins	 including	 VASP	 (Ser239)	
(Raslan	&	Naseem	2015).		
		 In	 order	 to	 test	 whether	 S.	 aureus	 lipoproteins	 cause	 VASP	
phosphorylation,	platelet	lysates	were	prepared	by	pre-incubating	platelets	with	
S.	aureus	membrane	protein	extracts.	Stimulation	of	platelets	by	an	agonist	leads	
to	 different	 positive	 feedback	 mechanisms,	 which	 suppress	 the	 platelet	
inhibitory	 signalling	 (Isenberg	 et	 al.	 2008).	 One	 such	 mechanism	 might	 be	
stimulation	of	 CD36	 that	 causes	 activation	of	NOX2	 (NADPH	oxidase	2),	which	
increases	 the	 level	 of	 reactive	 oxygen	 intermediates	 (ROI)	 and	 thus	 dampens	
cGMP	 mediated	 inhibitory	 signalling	 (Magwenzi	 et	 al.	 2015;	 Isenberg	 et	 al.	
2008).	 In	 order	 to	 test	 whether	 S.	 aureus	 lipoproteins	 inhibit	 feedback	
mechanisms	mediated	through	CD36	for	agonist	induced	VASP	phosphorylation,	
lysates	 were	 prepared	 of	 platelets	 pre-incubated	 with	 S.	 aureus	 membrane	
proteins	 and	 stimulated	 with	 CRP-XL.	 Western	 blotting	 for	 VASP	
phosphorylation	at	Ser239	and	Ser157	(Figure	6.2A),	showed	no	effect	on	VASP	
in	presence	of	S.	aureus	lipoproteins.	Nor	was	there	any	effect	on	agonist	induced	
VASP	 phosphorylation	 on	 platelets	 pre-incubated	 with	 S.	 aureus	 lipoproteins	
(Figure	 6.2).	 These	 data	 suggest	 that	 S.	 aureus	 lipoproteins	 do	 not	 induce	
increase	 in	 cAMP	 or	 cGMP	 levels	 in	 platelets.	 Also	 VASP	 phosphorylation	was	
seen	on	both	Ser239	and	Ser157	sites	without	any	difference	on	use	of	either	PGI	
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Figure	 6.2:	 S.	 aureus	 lipoproteins	 do	 not	 cause	 or	 affect	 VASP	
phosphorylation.	 A.	 Representative	 western	 blot	 for	 VASP	 phosphorylation	 at	
Ser157	and	Ser239	in	platelet	lysates	made	on	incubation	with	PGI,	PAPA	NONOate	
(NO	donor),	 CRP-XL	 and	S.	 aureus	 lipoproteins.	 14-3-3	 zeta	 blotted	 as	 a	 loading	
control.	B.	Data	plotted	as	adjustable	density	for	VASP	phosphorylation	at	Ser157	
and	 Ser239	 against	 14-3-3	 zeta	 loading	 control.	 Data	 represent	 mean	 values	 ±	
SEM.	 (n=3).	C.	 Representative	 western	 blot	 for	 VASP,	 upper	 band	 showing	 VASP	


























6.2.2:	 S.	 aureus	 lipoproteins	 do	 not	 affect	 tyrosine	 phosphorylation	 or	
protein	kinase	C	activity	stimulated	by	CRP-XL.	
	 Platelets	express	many	receptor	and	non-receptor	linked	protein	tyrosine	
kinases	 (PTK’s)	 like	Syk	 (Golden	et	al.	 1986;	Gao	et	al.	 1997;	Senis	et	al.	 2015;	
Kralisz	&	Cierniewski	2000)	and	stimulation	by	agonists	causes	their	activation.	
CRP-XL	 activates	 platelets	 in	 a	 manner	 similar	 to	 collagen	 (Polanowska-
Grabowska	 et	 al.	 2003).	 Collagen	 induced	 platelet	 activation	 causes	 tyrosine	
phosphorylation-dependent	activation	of	phospholipase	Cγ2	(PLCγ2)	(Ezumi	et	
al.	 1998)	 and	 is	 the	 physiological	 platelet	 agonist	 that	 has	 been	 identified	 to	




stimulation	 of	 platelets,	 the	 effect	 on	 platelet	 signalling	 can	 be	 assessed	 (Diaz-
Ricart	et	al.	1999;	Zurbano	et	al.	2003).		
The	 protein	 kinase	 C	 (PKC)	 family	 of	 enzymes	 transduces	 numerous	
signals,	 promoting	 different	 stages	 of	 platelet	 activation	 (Yacoub	 et	 al.	 2006).	
Agonist	 induced	 PKC	 activation	 occurs	 via	 secondary	 messengers	 DAG	 and	
inositol	 1,4,5-trisphosphate	 (IP3)	 (Yoshida	 et	 al.	 1992).	 Binding	 of	 CRP-XL	 to	
GPVI	causes	 tyrosine	kinase	dependent	activation	of	PLCγ2	(Jarvis	et	al.	2002).	
Activated	 PLCγ2	 stimulates	 synthesis	 of	 DAG	 and	 inositol	 1,4,5-trisphosphate	
(IP3).	IP3	induces	an	increase	in	intracellular	calcium	levels	by	stimulating	Ca2+	
release	from	intracellular	calcium	stores	(Li	et	al.	2010).	Binding	of	Ca2+	to	PKC	
promotes	 its	 tethering	 to	membrane	phosphotydylserine,	 thus	allowing	DAG	to	
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bind.	Binding	of	DAG	causes	a	conformational	change	in	PKC,	allowing	release	of	
pseudo-substrate,	 empting	 the	 catalytically	 active	 pocket	 that	 causes	
phosphorylation	of	nearby	substrates	(Lenz	et	al.	2002).	Activated	PKC	isoforms	
are	involved	in	platelet	granule	release	(Konopatskaya	et	al.	2011),	thromboxane	
synthesis	 (Yacoub	 et	 al.	 2006),	 platelet	 spreading	 (Harper	 &	 Poole	 2010),	
integrin	 activation,	 aggregation	 and	 thrombus	 formation	 (Yacoub	 et	 al.	 2006).	
The	 phosphorylation	 profile	 of	 PKC	 substrates	 is	 another	marker	 for	 studying	
platelet	signalling.		
To	 examine	 the	 effect	 of	 S.	 aureus	 lipoproteins	 on	 platelet	 signalling,	
tyrosine	phosphorylation	and	PKC	substrate	phosphorylation	stimulated	by	CRP-
XL,	 in	 platelets	 pre-treated	 with	 S.	 aureus	 membrane	 protein	 extracts,	 was	
analysed.	 There	 was	 no	 effect	 of	 S.	 aureus	 lipoproteins	 on	 tyrosine	
phosphorylation	 (Figure	6.3A)	or	PKC	 substrate	phosphorylation	 (Figure	6.3B)	
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Figure	 6.3:	 S.	 aureus	 lipoproteins	 do	 not	 cause	 or	 affect	 tyrosine	
phosphorylation	or	PKC	substrate	phosphorylation.	A.	Representative	western	
blot	 tyrosine	 phosphorylation	 (4G10)	 on	 stimulation	 with	 CRP-XL	 (30	 sec),	 S.	
aureus	lipoproteins	(10	min)	and	CRP-XL	(30	sec)	on	platelets	pre-incubated	with	
S.	 aureus	 lipoproteins	 (10	 min).	 B.	 Representative	 western	 blot	 showing	 PKC	
substrate	 phosphorylation	 on	 stimulation	 with	 CRP-XL	 (30	 sec),	 S.	 aureus	



























	 S.	 aureus	 lipoproteins	 inhibit	 platelet	 activation	 but	 do	 not	 cause	 VASP	
phosphorylation	nor	do	 they	 affect	 the	 initial	 tyrosine	phosphorylation	 or	PKC	
substrate	 phosphorylation	 caused	 by	 physiological	 agonists.	 From	 these	
signalling	 assays	 it	 can	 be	 speculated	 that	 the	 interaction	 between	 S.	 aureus	
lipoproteins	 and	 CD36	 might	 not	 be	 causing	 any	 intracellular	 changes	 in	
platelets.	To	see	what	other	molecules	this	 interaction	(S.	aureus	 lipoproteins	–	
CD36)	might	influence,	mass	spec	data	were	analysed	by	string	analysis	(Jensen	
et	 al.	 2009)	 (Figure	 6.4).	 By	 focusing	 on	 CD36,	 it	 was	 seen	 that	 molecules	
predicated	to	interact	with	CD36	could	be	divided	into	three	groups	according	to	
their	cellular	locations	–	intracellular,	membrane	bound	or	extracellular	(Figure	
6.4).	 From	 the	 signalling	 analysis,	 the	 interaction	 between	 CD36	 and	 S.	aureus	
lipoproteins	 does	 not	 alter	 intracellular	 proteins	 known	 to	 be	 involved	 in	
activation,	 so	 membrane	 bound	 proteins	 were	 considered	 as	 a	 possible	
mechanism	of	inhibition.		
	 CD36	 is	 known	 to	 physically	 associate	 with	 integrin	 α3β1	and	 α6β1	 in	
human	 myeloma	 cells	 (Thorne	 et	 al.	 2000)	 and	 CD9,	 αIIb,	 and	 β3	 on	 human	
platelets	 (Miao	 et	 al.	 2001).	 String	 analysis	 (Jensen	 et	 al.	 2009)	 of	 the	 mass	
spectrometry	 data	 of	 platelet	 proteins	 associated	 with	 S.	 aureus	 lipoproteins	
showed	 the	 presence	 of	 β3,	 αIIb,	 GPIb	 and	 GPV	 associated	with	 CD36	 (Figure	






















and	 CD9	 showed	 that	 the	 presence	 of	 S.	 aureus	 ΔltaS	 membrane	 proteins	
significantly	 increases	integrin	β3	co-precipitation	with	CD36	 in	comparison	 to	
samples	with	S.	aureus	ΔltaS	lgt	membrane	proteins	or	control	(Figure	6.5).		The	
co-immunoprecipitation	 of	 CD36	 varied,	 in	most	 instances	 it	was	 decreased	 in	
presence	of	S.	aureus	lipoproteins,	which	might	be	due	to	the	less	ability	of	anti-
CD36	 antibody	 to	 access	 its	 binding	 site,	 as	 in	 some	 instances	 S.	 aureus	
lipoproteins	 might	 occupy	 and	 hide	 it.	 The	 association	 of	 proteins	 binding	 to	
CD36	was	 calculated	 by	 adjusting	 the	 densities	 according	 to	 the	 relative	 CD36	
pull	down	using	Image-J.	There	was	no	detectable	αIIb	or	CD9	on	western	blots	
for	any	of	the	samples	including	control	(in	absence	of	membrane	proteins	form	
S.	 aureus	 ΔltaS	 and	 S.	 aureus	 ΔltaS	 lgt),	 suggesting	 that	 the	 experimental	
conditions	(washing)	used	might	not	be	suitable	to	keep	the	association	between	
this	proteins	and	CD36	intact.	This	also	suggests	that	interaction	between	αIIb	or	
CD9	with	 CD36	might	 not	 be	 as	 strong	 as	 seen	with	 β3.	 Presence	 of	 S.	aureus	
ΔltaS	membrane	proteins	increased	the	co-precipitation	of	β3	with	CD36.	
	 Agonist	 induced	 platelet	 activation	 was	 inhibited	 by	 S.	 aureus	
lipoproteins.	To	check	whether	 increased	CD36-β3	association	due	 to	S.	aureus	
lipoproteins	 was	 changed	 in	 the	 presence	 of	 an	 agonist	 (CRP-XL),	 co	
immunoprecipitation	 for	 CD36	 on	 CRP-XL	 stimulated	 platelets	was	 done.	 At	 1	
μg/ml	 CRP-XL,	 inhibition	 of	 platelet	 aggregation	 by	 S.	 aureus	 lipoproteins	was	
overcome.	The	same	effect	was	observed	on	CD36-β3	association,	on	treatment	
of	 platelets	with	 1	 μg/ml	 CRP-XL,	 the	 increased	 association	 between	 CD36-β3	
caused	by	S.	aureus	lipoproteins	was	inhibited	(Figure	6.6).		At	concentration	of	
	 145	
0.1	 μg/ml	 the	 increase	 in	 association	between	CD36-β3	was	 seen	 (Figure	6.6).	
Thus	 increased	CD36-β3	 association	 and	 inhibition	of	 platelet	 activation	might	
be	 correlated.	 Stimulation	 of	 platelets	 with	 CRP-XL	 only	 also	 slightly	 but	
significantly	 increases	 the	 CD36-β3	 association,	 which	 suggests	 that	 this	
association	 might	 play	 role	 in	 platelet	 activation	 but	 in	 presence	 of	 S.	 aureus	
lipoproteins	 balance	 between	 this	 associations	 is	 affected	 suggesting	 it	 might	
play	 role	 in	 inhibition	 of	 platelet	 activation.	 	 Also,	 stimulation	 of	 platelets	 pre-
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lgt	 membrane	 proteins	 were	 co-immunoprecipitated	 for	 CD36	 using	 anti-CD36	










































CRP-XL	(μg/ml)	 -	 -	 1	 1	 0.1	 0.1	
	
Figure	6.6:	Co-precipitation	of	 integrin	β3	with	CD36.	Platelet	treated	with	S.	
aureus	 ΔltaS	 membrane	 proteins	 and	 different	 concentrations	 of	 CRP-XL	 were	
lysed	and	co-immunoprecipitated	for	CD36	using	anti-CD36	antibody	and	Protein	G	
magnetic	beads.	Co-immunoprecipitation	samples	and	platelet	 lysate	as	a	control	

































6.2.4:	 The	 interaction	 between	 S.	 aureus	 lipoproteins	 and	 CD36	 is	
responsible	for	the	increased	association	between	integrin	β3	and	CD36.	
	 In	 the	presence	of	S.	aureus	 lipoproteins,	 the	association	between	CD36-
β3	was	increased	significantly.	S.	aureus	lipoproteins	bind	to	CD36	and	inhibition	
of	 platelet	 activation	 occur.	 To	 analyze	 whether	 the	 interaction	 between	 S.	
aureus	lipoproteins	and	CD36	was	responsible	for	increased	association	between	
CD36-β3,	binding	of	biotinylated	S.	aureus	 lipoproteins	to	CD36	was	blocked	by	
an	 anti-CD36	 antibody.	 After	 co-precipitating	 S.	 aureus	 lipoproteins	 using	
streptavidin	beads,	the	reaction	mixture	was	examined	for	CD36	and	β3.	Control	
showed	 the	 presence	 of	 β3	 suggesting	 direct	 interaction	 between	 this	 protein	
and	streptavidin	beads.	The	plot	(Figure	6.7)	represents	the	relative	densities	for	
the	bands	obtained,	 as	 it	was	not	possible	 to	 calculate	 the	 adjustable	densities	
against	the	S.	aureus	 lipoproteins	due	to	the	presence	of	numerous	bands.	Even	
though	the	normalization	was	not	possible	but	from	the	relative	band	densities	it	
was	 observed	 that,	 as	 the	 concentration	 of	 anti-CD36	 antibody	was	 increased,	
the	amount	of	CD36	as	well	as	β3	was	significantly	decreased	(Figure	6.7).	Thus	
inhibition	 of	 the	 interaction	 between	 S.	 aureus	 lipoproteins	 and	 CD36,	 also	
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Figure	6.7:	Role	of	the	CD36	–	S.	aureus	lipoproteins	interaction	in	increased	
CD36-β3	 association.	 Platelet	 treated	 with	 biotinylated	 S.	 aureus	 ΔltaS	
membrane	 proteins	 and	 different	 concentrations	 of	 anti-CD36	were	 lysed	 and	 co	
precipitated	 for	 biotinylated	 S.	 aureus	 lipoproteins	 using	 streptavidin	 beads.	 Co	
precipitation	 samples	 were	 western	 blotted	 for	 integrin	 β3,	 CD36	 and	 S.	 aureus	


























6.2.5:	 Interaction	 between	 S.	 aureus	 lipoproteins	 and	 CD36	 do	 not	 affect	
FcΥRIIa	association.	
	 Fc	 receptors	 are	 surface	 proteins	 that	 have	 binding	 affinity	 for	 the	 Fc	
portion	of	an	antibody	(Ramsland	et	al.	2011).	Fc	receptors	play	a	significant	role	
in	 immune	 and	 inflammatory	 responses	 and	 are	 expressed	 on	 macrophages	
(Dorrington	 1976),	neutrophils	 (Repp	 et	 al.	 1991),	 natural	 killer	 cells,	 B-
lymphocytes	 (Perussia	 et	 al.	 1984),	 mast	 cells	 (Malbec	 &	 Daëron	 2007)	 and	
platelets	 (Shido	 et	 al.	 1995).	 FcΥRIIa	 is	 the	 Fc	 receptor	 present	 on	 platelets	







physiological	 agonists	 (Chapter	 4).	 Also	 FcΥRIIa	 receptor	 plays	 role	 in	
amplification	 of	 platelet	 activation	 signalling	 mediated	 via	 integrin	 αIIbβ3	
(Boylan	et	al.	2008).	There	is	no	reported	evidence	of	direct	interaction	between	
FcΥRIIa	 and	 integrin	 αIIbβ3,	 but	 S.	 aureus	 lipoproteins	 increases	 the	 CD36-β3	
association	 and	 FcΥRIIa	 is	 significant	 in	 S.	 aureus	 mediated	 platelet	 activation	
(Arman	et	al.	2014)	that	makes	it	important	to	explore	its	involvement.	In	order	
to	 investigate	 if	 S.	 aureus	 lipoproteins	 –	 CD36	 interaction	 affect	 or	 cause	 any	
interaction	 with	 FcΥRIIa,	 co-immuno	 precipitation	 for	 FcΥRIIa	 was	 done	 on	
platelets	 incubated	 with	 S.	 aureus	 ΔltaS	membrane	 proteins	 and/or	 CRP-XL.	
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Western	blotting	the	co-immuno	precipitated	samples	for	integrin	β3	and	CD36,	
it	 was	 observed	 that	 none	 of	 them	 were	 co-precipitated	 with	 FcΥRIIa	 and	
presence	of	S.	aureus	ΔltaS	membrane	proteins	and/or	CRP-XL	did	not	cause	any	
of	 them	 to	 associate	 (Figure	 6.8).	 These	 data	 suggests	 that	 there	might	 be	 no	
physical	level	association	between	integrin	β3	and	FcΥRIIa	or	CD36	and	FcΥRIIa	
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Figure	 6.8:	 Co-precipitation	 of	 integrin	 β3	 and	 CD36	with	 FcΥRIIa.	Platelets	
pre-incubated	with	S.	aureus	ΔltaS	membrane	proteins	and/or	CRP-XL	were	lysed	
and	 co-immunoprecipitated	 for	 FcΥRIIa	 using	 anti	 CD32	 antibody	 (anti	 Fc	




















2015).	 To	 test	 the	 effect	 of	 kinase	 activity	 on	 platelets	 treated	 with	 S.	 aureus	
lipoproteins,	tyrosine	phosphorylation	and	PKC	substrate	phosphorylation	were	
examined.	 The	 phosphorylation	 profile	 showed	 that	 there	 was	 no	 effect	 on	
protein	 phosphorylation	 caused	 by	 agonists	 on	 platelets	 pre-incubated	with	 S.	
aureus	 lipoproteins	 (Figure	6.3).	Thus	S.	aureus	 lipoproteins	are	able	 to	 inhibit	
platelet	activation	without	affecting	protein	phosphorylation	and	initial	platelet	
signalling.		
	 Normal	 haemostasis	 is	 maintained	 by	 controlling	 platelet	 activation.	
Under	 physiological	 conditions,	 platelet	 activation	 is	 inhibited	 by	 two	 major	
vasodilators	released	by	endothelial	cells	and	platelets	 themselves-	nitric	oxide	
and	prostacyalin	(PGI2)	(Rivera	et	al.	2009).	Both	control	the	VASP	proteins	that	
regulate	 the	 actin	 dynamics	 and	 integrin	 activation	 in	 platelets	 preventing	
platelet	 activation	 (Aszodi	 et	 al.	 1999).	 CD36	 plays	 a	 part	 in	 a	 feedback	
mechanism	 by	 increasing	 the	 ROIs	 that	 control	 nitric	 oxide	 levels,	 thus	
decreasing	 intracellular	 cGMP	 concentrations	 and	 promote	 platelet	 activation	
(Magwenzi	 et	 al.	 2015).	 To	 explore	 whether	 CD36	 -	 S.	 aureus	 lipoprotein	
interactions	affect	this	modulatory	ability	of	CD36,	VASP	phosphorylation	caused	
in	 platelets	 treated	 with	 S.	 aureus	 lipoproteins	 was	 assessed.	 S.	 aureus	
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lipoproteins	had	no	effect	on	resting	platelets	VASP	phosphorylation	nor	did	 it	
have	 any	 effect	 on	 agonist	 induced	 VASP	 phosphorylation.	 This	 suggests	 that	
inhibition	 of	 platelet	 activation	 by	 S.	 aureus	 lipoproteins	 does	 not	 involve	
increase	 in	 cyclic	 guanosine	 monophosphate	 (cGMP)	 or	 cyclic	 adenosine	
monophosphate	levels	(cAMP)	and	subsequent	phosphorylation	of	VASP.		





	 CD36	 can	 associate	 with	 platelet	 integrins	 (Miao	 et	 al.	 2001).	 To	 see	
whether	 this	 association	 is	 affected	 by	 S.	 aureus	 lipoproteins,	 co-immuno	 –
precipitation	of	CD36	on	platelets	treated	with	S.	aureus	 lipoproteins	was	done.	
It	 showed	 that	 in	 the	 presence	 of	 S.	 aureus	 lipoproteins,	 association	 between	
CD36	and	platelet	integrin	β3	was	significantly	increased	and	this	increase	was	
dependent	on	interactions	between	S.	aureus	lipoproteins	and	CD36.	Integrin	β3	
is	 an	 important	 component	 of	 αIIbβ3,	 a	 major	 integrin	 on	 platelets.	 On	
incubation	of	platelets	with	S.	aureus	lipoproteins,	increased	PAC-1	binding	(the	
antibody	 that	binds	 to	active	 from	of	αIIbβ3)	caused	by	agonists	was	 inhibited	
(Chapter	4).	Activation	of	αIIbβ3,	 leads	 to	 its	clustering,	 followed	by	binding	of	
ligands	 to	 the	 clustered	αIIbβ3	 (Gaul	et	al.	 2015).	One	of	 the	major	 ligands	 for	
active	 αIIbβ3	 is	 fibrinogen.	 In	 the	 presence	 of	 S.	 aureus	 lipoproteins	 agonist	
induced	 fibrinogen	binding	and	 spreading	on	 fibrinogen	was	 reduced	 (Chapter	
4).	 These	 results	 again	 suggest	 that	 S.	 aureus	 lipoproteins	 inhibit	 αIIbβ3	
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activation.	 Direct	 physical	 level	 associations	 between	 CD36	 and	 integrin	 β3	 in	





the	 presence	 or	 absence	 of	 S.	 aureus	 lipoproteins.	 In	 the	 case	 of	 CD9,	 mass	
spectrometry	 data	 and	 co-immunoprecipitation	 assay	 did	 not	 show	 any	 direct	
association	of	CD36	with	CD9.	Also	due	 to	differences	 in	 the	effect	of	S.	aureus	
lipoproteins	on	mice	and	human	platelets,	FcΥRIIa	was	thought	to	be	involved,	as	
mice	 platelets	 lacks	 FcΥRIIa.	 But	 co-immunopreciptiation	 assays	 showed	 no	
association	 of	 FcΥRIIa	with	 integrin	 β3	 and	CD36	 in	 absence	 or	 presence	 of	 S.	
aureus	lipoproteins.		
The	 increase	 in	 association	 between	 integrin	 β3	 and	CD36	 caused	by	S.	
aureus	 lipoproteins	 is	 not	 seen	 in	 the	 presence	 of	 higher	 concentrations	 of	
agonist	(Figure	6.6).	Earlier	inhibitory	studies	have	shown	that	on	increasing	the	
concentration	 of	 agonist,	 inhibition	 of	 platelet	 aggregation	 caused	 by	S.	aureus	
lipoproteins	is	inhibited	(Chapter	4).	The	fact	that	high	concentration	of	agonist	
inhibit	 the	 increased	 β3	 -	 CD36	 interaction,	 which	 in-turn	 abrogate	 inhibitory	
effect	 of	 S.	aureus	 lipoproteins	 suggests	 that	 this	 association	might	 be	 the	 key	








	 Under	 normal	 physiological	 conditions,	 platelets	 are	 one	 of	 the	 most	
abundant	cells	 in	human	blood.	Therefore	during	bacteraemia,	platelets	 can	be	
speculated	to	be	the	first	host	cell	that	comes	in	contact	with	pathogen	(Cox	et	al.	
2011).	 Numerous	 bacteria	 can	 modulate	 platelet	 function	 (Fitzgerald	 et	 al.	
2006).	 A	 role	 for	 platelets	 in	 host	 defence	 has	 not	 been	 clearly	 elucidated	 but	
platelets	are	known	to	play	a	part	in	immune	function	by	secreting	cytokines	that	
recruit	immune	cells	(Hamzeh-Cognasse	et	al.	2015)	and	by	directly	interacting	
with	 immune	 cells	 (Etulain	 et	 al.	 2015),	 aiding	 their	 function.	 Thus,	 by	
modulating	platelet	 function,	bacteria	can	regulate	this	platelet	response	which	
might	aid	in	its	survival	in	host.		
S.	 aureus	 is	 one	 of	 the	 major	 pathogenic	 bacteria	 which	 has	 been	
extensively	 studied	 for	 its	 ability	 to	 modulate	 platelet	 activity.	 Numerous	 S.	
aureus	 surface	 proteins	 are	 known	 to	 interact	 with	 platelets	 either	 directly	
(Miajlovic	et	al.	2010)	or	via	a	plasma	protein	bridge	(Fitzgerald,	Loughman,	et	
al.	 2006;	Loughman	et	al.	 2005)	 and	 cause	 their	 activation.	Along	with	 surface	





the	 host	 (Wardenburg	 et	 al.	 2006).	 S.	 aureus	 lipoproteins	 also	 show	 binding	
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aggregation	 lag	 time	 and	 showed	 reduced	 binding	 ability	 to	 platelets.	 The	 S.	
aureus	 lipoproteins	 biogenesis	 process	 involves,	 acylation	 of	 pro-lipoproteins	
anchored	in	the	cell	membrane	via	a	signal	peptide	by	lipoprotein	diacylglyceryl	
transferase	 (Lgt)	 and	 then	 removal	 of	 the	 signal	 peptide	 by	 lipoprotein	 signal	
peptidase	 (Lsp)	 (Nakayama	 et	 al.	 2012).	 The	 acyalted	 portion	 of	 lipoproteins	
inside	 the	 cell	 membrane	 functions	 as	 an	 anchor	 once	 the	 signal	 peptide	 is	
truncated	(Blanc	et	al.	2013).	In	S.	aureus	lgt	mutants	a	greater	amount	of	non–
acylated	 pro-lipoproteins	 are	 expressed	 on	 the	 bacterial	 surface	 and	 as	 well	
released	 in	 supernatant	 (Stoll	 et	 al.	 2005).	 S.	 aureus	 lipoproteins	 lacking	
acylation	 are	 not	 recognized	 by	 host	 immune	 cells	 and	 can	 persist	 longer	
(Bubeck	Wardenburg	et	al.	2006).	By	this	observation	it	can	be	speculated	that	
there	is	a	direct	interaction	between	S.	aureus	lipoproteins	and	immune	cells,	as	











milieu	 are	 lipoproteins	 (Stoll	 et	 al.	 2005).	 The	 extracted	 S.	 aureus	 membrane	
proteins	showed	an	ability	to	bind	platelets,	whereas	in	comparison	to	wild	type,	






aureus	 lgt	ΔltaS	 did	 not	 show	any	 effect.	 The	TX-114	phase	 extraction	method	
was	used	to	extract	hydrophobic	membrane	proteins	(Li	et	al.	2008;	Asanuma	et	
al.	 2011;	 Cockayne	 et	 al.	 1998)	 and	 on	 using	 this	 method	 the	 extract	 of	
lipoproteins	from	S.	aureus	showed	contamination	with	lipotechioc	acid	(LTA).	S.	





Stimulation	 of	 platelets	 by	 a	 physiological	 agonist	 causes	 numerous	
signalling	and	sequential	events	leading	to	platelet	activation	(Watson	&	Gibbins	
1998;	 Sambrano	 et	 al.	 2001).	 Sustained	 increases	 in	 the	 level	 of	 intracellular	
calcium	 are	 essential	 for	 activity	 of	 many	 enzymes	 (kinases)	 that	 cause	
intracellular	signalling	(Li	et	al.	2010),	integrin	activation	(Tsuboi	2002),	platelet	
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spreading	 (Naik	 &	 Naik	 2003)	 and	 thrombus	 formation.	 Initial	 signalling	
stimulated	by	 a	physiological	 agonist	 on	platelets	 pre-incubated	with	S.	aureus	
ΔltaS	 membrane	 proteins	 was	 not	 significantly	 different	 from	 controls.	 	 Also	
sustained	 increases	 in	 intracellular	calcium	 levels	caused	by	 integrin	activation	
in	 platelets	 were	 inhibited	 on	 preincubation	 with	 S.	 aureus	 ΔltaS	 membrane	
proteins.	 The	 thrombus	 formation	 kinetics	 on	 incubation	 with	 S.	 aureus	 ΔltaS	
membrane	proteins	showed	that	initial	platelet	adhesion	to	the	collagen	coated	
surface	 was	 not	 affected	 but	 a	 later	 stable	 thrombus	 was	 not	 formed.	 This	
suggests	 that	 the	 later	 stages	 of	 platelet	 activation	 are	 inhibited	 on	 pre-
incubation	of	platelets	with	S.	aureus	ΔltaS	membrane	proteins	without	affecting	
initial	 adhesion	 or	 signaling	 events	 caused	 by	 known	 physiological	 platelet	
agonists.	 There	 was	 no	 effect	 seen	 of	 membrane	 proteins	 extracted	 from	 S.	
aureus	lgt	ΔltaS	thus	suggesting	role	of	S.	aureus	lipoproteins	in	this	inhibition.		
S.	 aureus	 lipoproteins	 inhibit	 PAC-1	 binding	 i.e.	 activation	 of	 integrin	
αIIbβ3	 and	 binding	 of	 fibrinogen,	 both	 events	 necessary	 for	 platelet-platelet	
binding	and	 formation	of	an	aggregate	(Bennett	2005).	Thus	on	pre-incubation	
of	 platelets	 with	 S.	 aureus	 ΔltaS	 membrane	 proteins	 platelet	 aggregation	 was	
inhibited.		Stable	thrombus	formation	at	an	injury	site	is	the	result	of	interaction	
between	 platelets	 and	 extracellular	matrix	 proteins	 that	 leads	 to	 activation	 of	
platelets	(Kroll	et	al.	1991)		and	release	of	granules	(Whiteheart	2011)	that	aid	in	
recruitment	 and	 activation	 of	 additional	 platelets.	 On	 release	 of	 granules,	
platelets	 P-selectin	 molecules	 are	 expressed	 on	 the	 activated	 platelet	 surface	
(Koedam	 et	 al.	 1992).	 On	 pre-incubation	 of	 platelets	 with	 S.	 aureus	 ΔltaS	
membrane	 proteins	 P-selectin	 exposure	 caused	 by	 physiological	 agonists	 was	
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inhibited,	which	suggests	inhibition	of	granule	release.		Lack	of	granules	leads	to	
inhibition	 of	 platelet	 recruitment	 and	 stable	 platelet	 –	 platelet	 interaction,	
causing	 unstable	 thrombus	 formation	 (Whiteheart	 2011).	 Pre	 incubation	 of	
platelets	 with	 S.	 aureus	 ΔltaS	 membrane	 proteins	 also	 causes	 inhibition	 of	
platelet	 spreading	 on	 fibrinogen.	 Binding	 of	 activated	 integrin	 αIIbβ3	 to	
fibrinogen	 causes	 out-side	 in	 signalling	 which	 leads	 to	 cytoskeletal	
rearrangements	 in	 platelets	 leading	 to	 platelet	 spreading	 (Lee	 et	 al.	 2012).	
Inhibition	of	platelet	spreading	also	suggests	 inhibition	of	 integrin	αIIbβ3	by	S.	
aureus	ΔltaS	membrane	proteins.	Control	of	membrane	proteins	extracted	from	
S.	 aureus	 lgt	 ΔltaS	 did	 not	 show	 any	 effect	 on	 platelet	 activation	 suggesting	
involvement	of	S.	aureus	lipoproteins	in	inhibition	of	integrin	αIIbβ3.	
7.3.	 Inhibition	of	platelet	 activation	by	S.	aureus	 lipoproteins	 is	mediated	
via	CD36.	




with	S.	aureus	 lipoproteins	 did	 not	 show	TLR-2	 to	 be	 present.	 This	 absence	 of	
TLR2	might	be	due	to	the	low	abundance	of	TLR2	molecules	present	on	platelets	
(Cognasse	 et	 al.	 2005).	 	 On	 neutralization	 of	 TRL2	 on	 the	 platelet	 surface,	
inhibition	 of	 platelet	 activation	 caused	 by	 S.	 aureus	 lipoproteins	 was	 not	
abrogated.	 Stimulation	 of	 platelet	 TRL2	 causes	 an	 activation	 response	 in	
platelets	 (Fälker	 et	al.	 2014)	whereas	 S.	aureus	 lipoproteins	 caused	 inhibition.		
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These	 findings	 indicated	 that	 the	 effect	 of	 S.	 aureus	 lipoproteins	 on	 platelet	
function	is	probably	not	via	TLR-2.		
The	 functional	 relationship	 of	 scavenger	 receptors	 and	 modified	
lipoproteins	is	well	established	in	atherosclerosis	and	haemostasis	(Canton	et	al.	
2013).	 Scavenger	 receptors	 are	 known	 to	 recognise	 and	 remove	 modified	
lipoproteins	(Zingg	et	al.	2000).	Platelets	express	scavenger	receptors	like	CD36,	
SRB1,	 CD68	 and	 LOX1	 (Valiyaveettil	 &	 Podrez	 2009).	 Oxidised	 high-density	
lipoprotein,	on	 interaction	with	SRB1,	 inhibits	platelet	activation	 (Valiyaveettil,	
Kar,	 Ashraf,	 Byzova,	 Febbraio	 &	 E.	 a	 Podrez	 2008).	 But	 neither	 mass	
spectrometry	 data	 from	 platelet	 proteins	 co-precipitated	 with	 S.	 aureus	
lipoproteins,	nor	platelet	SRB1	neutralisation	showed	that	S.	aureus	lipoproteins	
bind	 SRB1	 or	 functionally	 alter	 platelet	 function	 via	 it.	 Also	 other	 than	 CD36,	
mass	 spectrometry	 data	 from	 platelet	 proteins	 co-precipitated	 with	 S.	 aureus	
lipoproteins	 did	 not	 show	 the	 presence	 of	 any	 other	 scavenger	 receptor.	 On	
blocking	CD36,	 inhibition	of	platelet	activation	caused	by	S.	aureus	 lipoproteins	
was	 abrogated,	 indicating	 that	 CD36	 not	 only	 binds	 S.	aureus	 lipoproteins,	 but	
also	was	responsible	for	functional	effect	caused	by	them.		
CD36	 is	 also	 known	 as	 a	 thrombospondin	 receptor	 (Nergiz-Unal	 et	 al.	
2011;	 Silverstein	 &	 Febbraio	 2009;	 Bull	 et	 al.	 1994).	 The	 interaction	 of	 CD36	
with	its	ligands	causes	production	of	reactive	oxygen	intermediates,	neutralizing	
NO	and	thus	promotes	platelet	activation	via	this	positive	 feedback	mechanism	





inhibited	 by	 interaction	 between	 S.	 aureus	 lipoproteins	 and	 CD36.	 Platelet	
activation	and	signalling	caused	via	CD36	upon	interaction	with	oxidised	LDL	is	
known	(Magwenzi	et	al.	 2015;	Silverstein	et	al.	 2010).	The	 interaction	of	CD36	
with	ligands	leads	to	activation	of	Syk	kinases	and	subsequent	phosphorylation	
causes	 platelet	 activation	 (Silverstein	 et	al.	 2010).	However,	 the	 presence	 of	S.	
aureus	lipoproteins	did	not	affect	the	tyrosine	and	VASP	phosphorylation	caused	
by	 CRP-XL,	 suggesting	 that	 S.	 aureus	 lipoproteins	 did	 not	 cause	 or	 affect	 the	
initial	 signalling.	 Focusing	 around	 proteins	 interacting	 with	 CD36	 in	 Mass	
spectrometry	 data	 from	 platelet	 proteins	 co-precipitated	 with	 S.	 aureus	
lipoproteins,	 I	 found	 three	 clear	 divisions	 (extracellular,	 intracellular	 and	
membrane	 proteins)	 in	 the	 interaction	 patterns.	 In	 the	 case	 of	 extracellular	
proteins,	 it	 can	 be	 proposed	 that	 their	 normal	 interaction	 with	 CD36	 in	 the	
presence	 of	 S.	 aureus	 lipoproteins	 will	 be	 altered	 and	 thus	 won’t	 cause	 their	
normal	physiological	effect	on	platelets.	From	the	signalling	data	obtained	it	can	
be	speculated	that	the	intracellular	proteins	were	not	affected	by	CD36-	S.	aureus	
lipoproteins	 interaction.	Thus	 the	membrane	proteins	 interacting	with	CD36	 in	
the	presence	of	S.	aureus	 lipoproteins	might	be	 the	main	contributing	 factor	 in	
inhibition	of	platelet	activation.			
CD36	associates	with	platelet	membrane	proteins	β3,	αIIb	and	CD9	(Miao	
et	 al.	 2001);	 the	 functional	 significance	 of	 these	 interactions	 is	 not	 yet	
established.	 Co-immunoprecipitation	 analysis	 showed	 that	 the	 presence	 of	 S.	
aureus	 lipoproteins	 affects	 the	 CD36-β3	 association.	 During	 platelet	 activation,	
conformational	 changes	 in	 integrin	αIIbβ3	change	 its	 affinity	 state	 from	 low	 to	
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high,	allowing	it	to	bind	its	ligands	which	leads	to	signalling	events	and	platelet	
activation	 (Mehrbod	 et	 al.	 2013).	 Activation	 of	 integrin	 αIIbβ3	 is	 proposed	 to	
occur	 by	 a	 clasping/unclasping	mechanism	 (Ma	 et	 al.	 2007).	 The	 extracellular	
region	 of	 αIIb	 and	 β3	 are	 clasped	 with	 each	 other	 until	 the	 transmembrane	
region	(Figure	7.1A)	(Kim	et	al.	2009).	Binding	of	talin	to	the	cytoplasmic	region	
of	β3	 initiates	an	unclasping	event	 that	 leads	 to	 conformational	 changes	 in	 the	
transmembrane,	and	subsequently	extracellular	domains	of	αIIbβ3	(Kahner	et	al.	
2012).	The	activation	phenomenon	is	seen	to	be	reversible,	as	on	detachment	of	
talin	 by	 other	 proteins	 (β3	 -	 endonexin)	 competing	 for	 the	 same	 site	 causes	
return	 of	 αIIbβ3	 to	 inactive	 conformation	 (Kashiwagi	 et	 al.	 1997).	 The	
equilibrium	 between	 proteins	 responsible	 for	 clasping	 and	 unclasping	 of	 αIIb	
and	 β3	 is	 speculated	 to	 be	 significant	 in	 deciding	 in	 fate	 of	 αIIbβ3	 activation	
(Figure	7.1	A)	(Ma	et	al.	2007).		
Association	 of	 other	 surface	 molecules	 with	 platelet	 integrin	 αIIbβ3	
occurs	(Miao	et	al.	2001),	but	the	manner	in	which	this	association	might	affect	
the	 equilibrium	of	 integrin	 activation	 is	unknown.	 It	 can	be	 speculated	 that	 an	
increase	in	CD36-β3	association	in	presence	of	S.	aureus	lipoproteins	might	affect	
the	equilibrium	and	block	the	normal	transition	of	integrin	αIIbβ3	from	inactive	









Figure	 7.1:	 Proposed	 mechanism	 of	 inhibition	 of	 platelet	 activation	 by	 S.	
aureus	 lipoproteins	 via	 CD36.	 A.	 Mechanism	 of	 activation	 of	 integrin	 αIIbβ3.	
Clasping	 and	 unclasping	 of	 integrin	 αIIbβ3	 is	 dependent	 on	 equilibrium	between	
suppressor	or	activator	(talin)	to	integrin	β3	(Ma	et	al.	2007).	B.	Proposed	model	of	
blockage	 of	 integrin	 αIIbβ3	 conformation	 change	 in	 presence	 of	 S.	 aureus	
lipoproteins.	 Increase	 in	CD36	-	β3	association	might	a.	directly	 inhibit	change	 in	
integrin	β3	conformation	or	b.	inhibit	binding	of	activator	proteins	to	integrin	β3.	
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7.4.	S.	aureus	 lipoproteins	 inhibit	platelet	activation	–	significance	 in	host	
pathogen	interaction.		
S.	 aureus	 –	 platelet	 interaction	 is	 speculated	 to	 be	 of	 significance	 in	
pathogenesis	 of	 bacteria,	 especially	 in	 bacterial	 endocarditis	 (Fitzgerald	 et	 al.	
2006).	Initiation	of	S.	aureus	–	platelet	plug	formation	is	thought	to	be	occurring	
via	 interaction	 of	 circulating	 S.	 aureus	 with	 platelets	 adhered	 to	 the	 damaged	
vessel	 surface	 (Werdan	 et	 al.	 2014).	 Numerous	 surface	molecules	 of	 S.	 aureus	
bind	 to	 platelets	 and	 even	 regulate	 platelet	 function	 but	 in	 any	 interaction	
(O’Brien	 et	 al.	 2002),	 avidity	 of	 the	 molecules	 interacting	 is	 significant.	 	 In	 a	
bacteria	 platelet	 interaction,	 along	 with	 the	 avidity	 between	 bacterial	 surface	
molecules	interacting	with	platelet	surface	molecules,	their	number	also	plays	a	
significant	 role.	 More	 the	 bacterial	 surface	 molecules	 able	 to	 bind	 platelets,	
readily	 the	 initiation	 of	 infection	 might	 occur.	 Bacteria	 mediated	 platelet	
aggregation	lag	time	is	considered	to	be	a	marker	in	understanding	the	number	
of	surface	molecules	involved	in	interaction,	lesser	the	lag	time	more	readily	the	
binding	 (Fitzgerald	 et	 al.	 2006),	 thus	 more	 surface	 molecules	 involved	 in	
interaction.		
In	 in-vivo	conditions,	which	 is	 reported	 to	be	 ion	depleted	condition	 for	
bacteria,	S.	aureus	 lipoproteins	might	 be	 expressed	 in	 high	 number	 as	most	 of	
them	are	involved	in	ion	transport	(Sheldon	&	Heinrichs	2012;	Horsburgh	et	al.	
2002).	 In	 an	 in	 vitro	 aggregation	 assay	 using	 S.	 aureus	 cell	 envelope	 extracts	
lacking	lipoproteins	showed	significantly	higher	 lag	time	compared	to	S.	aureus	
envelope	extract	with	lipoproteins.	Even	the	binding	assay	showed	that	S.	aureus	
whole	bacteria	 could	bind	 significantly	better	 in	presence	of	 lipoproteins.	 So	 it	
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can	 be	 speculated	 that	 in	 in-vivo	 ion	 limited	 conditions	 with	 high	 number	 of	
lipoproteins	 on	 the	 surface,	 S.	 aureus	 lipoproteins	 might	 be	 a	 significant	
component	in	initiation	of	S.	aureus	–	platelet	interaction.				
	 The	 platelet	 clot	 from	 S.	 aureus	 mediated	 bacterial	 endocarditis	 has	
reported	 to	show	the	presence	of	S.	aureus	 inside	 the	plug	(Pawar	et	al.	2004).	
This	observation	suggests	that	S.	aureus	survives	in	this	environment	and	might	




the	 thrombus.	 In	 the	 process	 of	 normal	 thrombus	 formation	 platelet	 release	
molecules	that	activate	and	recruit	additional	platelets,	but	it	also	inhibit	platelet	
activation	 to	 control	 growing	 thrombus	 (Vassbotn	 et	 al.	 1994).	 S.	 aureus	 also	
releases	 the	platelet	 inhibitory	molecules	 (Waller	et	al.	2013;	Shannon	&	Flock	
2004)	 that	might	 play	 the	 same	 role.	 Along	with	 controlling	 growing	 thrombi,	
ability	 of	 S.	 aureus	 to	 inhibit	 platelet	 activation	might	 contribute	 in	 release	 of	
bacteria	 into	 the	 blood	 flow	 to	 spread	 the	 infection.	 S.	aureus	 lipoproteins	 are	
released	into	the	extracellular	milieu	(Stoll	et	al.	2005).	So	inside	a	thrombus,	if	S.	
aureus	grows,	along	with	other	platelet	inhibitory	molecules	like	LTA	and	Efb,	it	
will	 also	 release	 its	 lipoproteins	 which	 will	 contribute	 in	 inhibiting	 platelet	
activation.		
S.	aureus	 lipoproteins	also	stimulate	endothelial	cells	to	release	NO	(Kim	
et	 al.	 2015),	 which	 is	 a	 potent	 inhibitor	 of	 platelet	 activation	 and	 also	 a	
vasodilator	 (Gardiner	 et	 al.	 1990).	 Thus,	 inhibition	 of	 platelet	 activation	 and	
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vasodilation	that	increases	the	blood	flow,	might	aid	in	rapid	spread	of	S.	aureus	
into	 the	host.	Another	advantage	of	S.	aureus	 lipoproteins	 causing	 inhibition	of	
platelet	activation	and	NO	release	 for	S.	aureus	might	be	 in	evasion	of	 immune	







silico	 analysis	 (Sheldon	 &	 Heinrichs	 2012).	 The	 TX-114	 extract	 of	 S.	 aureus	
showed	 the	 presence	 of	 numerous	 bands	 on	 SDS	 PAGE	 and	 co-
immunoprecipitation	 of	 CD36	 with	 S.	 aureus	 membrane	 proteins	 showed	
receptor	 binds	 multiple	 proteins.	 The	 platelet	 inhibitory	 effect	 of	 S.	 aureus	
membrane	proteins	was	only	seen	in	extracts	from	S.	aureus	ΔltaS	but	not	from	S.	
aureus	lgt	ΔltaS	that	suggests	involvement	of	S.	aureus	lipoproteins	in	functional	
blocking	 of	 platelets.	 Further	 characterization	 of	 these	 S.	 aureus	 lipoproteins	
involved	in	binding	to	CD36	and	inhibiting	platelet	activation	is	necessary.		
Separation	and	isolation	of	bacterial	lipoproteins	is	difficult	due	presence	
of	 hydrophobic	 moiety,	 but	 use	 of	 hydrophobic	 interaction	 high	 performance	
liquid	 chromatography	 (HPLC)	 is	 proposed	 to	 be	 successful	 (Hashimoto	 et	 al.	
2004).	 Even	 though	 it	 has	 been	 seen	 that	 gram	positive	 bacteria	 like	S.	aureus	
lack	 Lnt	 homolog	 of	 gram	 negative	 bacteria	 responsible	 for	 triacylation	 of	




et	 al.	 2011)	 will	 also	 be	 necessary,	 as	 acylation	 nature	 of	 lipopeptide	 might	
change	the	platelet	response	and	the	receptor	involved.				
S.	aureus	lipoproteins	are	proposed	to	be	a	vaccine	candidate	for	S.	aureus	
prophylaxis	 (Anderson	et	al.	 2012).	Knowledge	of	 the	 specific	 lipoproteins	and	




(Magwenzi	 et	 al.	 2015),	 but	 in	 the	 current	 study	 it	 was	 shown	 that	 S.	 aureus	
lipoproteins	 inhibit	 platelet	 activation	 via	 CD36.	 The	 interaction	 between	




(Förster	 Resonance	 Energy	 Transfer)	 technology	 which	 can	 evaluate	 the	
interaction	 of	 surface	 receptors	 on	 the	 cell	 surface	 (Maurel	 et	 al.	 2008)	 can	
provide	 significant	 information	on	 interaction	happening	on	 the	 cell.	 Also	high	
resolution	 microscopy	 like	 scanning	 electron	 microscopy	 or	 super	 resolution	




Confirmation	 of	 changes	 in	 association	 between	 CD36	 and	 β3	 might	
further	 led	 to	 understanding	 the	 mechanism	 by	 which	 the	 actual	 inhibition	
occurs.	The	current	study	focused	on	looking	at	the	association	of	CD36	with	β3,	
αIIb,	 CD9	 and	 FcγRIIa	 in	 presence	 of	 S.	 aureus	 lipoproteins	 by	 using	 co-
precipitation	experiments.	Change	in	association	between	CD36	and	β3	was	seen	
but	it	is	being	reported	that	CD36	can	associate	with	the	other	surface	receptors	
which	 we	 looked	 at	 (Miao	 et	 al.	 2001),	 but	 no	 association	 was	 found,	 thus	 it	
cannot	 be	 completely	 ruled	 out	 that	 S.	 aureus	 lipoproteins	 do	 not	 affect	
association	 of	 CD36	 with	 other	 surface	 proteins	 on	 platelets.	 So	 using	 above	
mentioned	techniques	the	association	between	CD36	and	other	surface	proteins	
can	be	looked	at.			
Another	 aspect	 that	 should	 be	 explored	 is	 the	 effect	 of	 S.	 aureus	
lipoproteins	 on	mouse	 platelets.	 The	mouse	 platelets	were	 not	 affected	 by	 the	
treatment	of	S.	aureus	lipoproteins.	Major	platelet	surface	receptor	known	to	be	
involved	 in	 S.	 aureus	 mediated	 human	 platelet	 activation	 is	 FcγRIIa.	 Mouse	
platelets	lack	FcγRIIa	(McKenzie	et	al.	1999)	and	it	should	be	explored	whether	
its	 presence	 on	 human	 platelets	 influences	 S.	 aureus	 lipoproteins	 mediated	
inhibition.	Use	of	transgenic	mice	model	consisting	FcγRIIa	receptor	(McKenzie	
et	al.	1999)	 for	 analyzing	 the	effect	of	S.	aureus	 lipoproteins	might	give	 insight	
into	 the	 role	 of	 this	 receptor	 in	 S.	 aureus	 lipoproteins	 mediated	 inhibition	 of	
platelet	activation.			
7.5.2.	Effect	of	CD36	-	β3	association	on	platelet	function.		






in	 which	 association	 of	 CD36	 with	 integrin	 β3	 affects	 platelet	 function	 is	
unknown.	 This	 study	 showed	 that	 an	 increase	 in	 CD36-β3	 association	 might	
result	 in	 inhibition	 of	 platelet	 activation	 and	 this	 needs	 to	 be	 further	 explored	
which	can	be	done	by	analyzing	CD36	knockout	mice.	Also	S.	aureus	lipoproteins	
can	 be	 used	 as	 a	 tool	 to	 explore	 the	 functional	 significance	 of	 association	
between	 CD36	 and	 β3.	 The	 further	 evaluation	 in	 this	 aspect	might	 led	 to	 be	 a	
novel	 inhibitory	mechanism	that	can	be	exploited	 for	designing	antithrombotic	
drug.		
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